Gemcitabine
Based on 276 publication(s) in Google Scholar
Gemcitabine (LY 188011) is a pyrimidine nucleoside analog antimetabolite and an antineoplastic agent. Gemcitabine inhibits DNA synthesis and repair, and can modulate autophagy. Gemcitabine induces apoptosis through the activation of p38 MAPK. Gemcitabine demonstrates efficacy in mouse models of pancreatic and breast cancer. Gemcitabine can be used for cancer research, such as pancreatic cancer, non-small cell lung cancer, and breast cancer.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.95%
- CAS 番号: 95058-81-4
- 分子式: C9H11F2N3O4
- 分子量:263.20
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
MedChemExpress(MCE)の使用を引用している文献 Gemcitabine
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Nat Med. 2024 Mar;30(3):749-761. [Abstract]
- Nature. 2019 Oct;574(7777):264-267. [Abstract]
- J Clin Oncol. 2026 Mar 2.
- Mol Cancer. 2024 Sep 30;23(1):215. [Abstract]
- Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Adv Mater. 2021 May;33(18):e2100949. [Abstract]
- Cell Res. 2020 Jul;30(7):574-589. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Cancer Commun (Lond). 2025 May 29. [Abstract]
- Nat Metab. 2025 Nov 13. [Abstract]
- Cancer Res. 2023 Sep 15;83(18):3059-3076. [Abstract]
- Hepatology. 2019 May;69(5):1995-2012. [Abstract]
- Nat Commun. 2025 Jul 17;16(1):6592. [Abstract]
- Nat Commun. 2024 Oct 2;15(1):8540. [Abstract]
- Acta Pharm Sin B. 2026 Mar 2.
- Acta Pharm Sin B. 2023 Oct;13(10):4253-4272. [Abstract]
- Sci Transl Med. 2021 Jan 20;13(577):eaba7401. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- Adv Sci (Weinh). 2025 May 20:e01042. [Abstract]
- Adv Sci (Weinh). 2025 Jan 21:e2409173. [Abstract]
- Adv Sci (Weinh). 2024 Nov 28:e2407519. [Abstract]
- Adv Sci (Weinh). 2024 Aug 23:e2400156. [Abstract]
- Adv Sci (Weinh). 2023 Nov;10(33):e2302498. [Abstract]
- Adv Sci (Weinh). 2023 Oct;10(30):e2303872. [Abstract]
- Adv Sci (Weinh). 2023 Apr;10(12):e2206004. [Abstract]
- Adv Sci (Weinh). 2022 May;9(15):e2105894. [Abstract]
- J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
- Theranostics. 2021 Mar 24;11(12):5650-5674. [Abstract]
- Chem Eng J. 2024 Sep 1.
- Chem Eng J. 2023 Nov 17, 147466.
- J Adv Res. 2025 Nov 5:S2090-1232(25)00874-4. [Abstract]
- J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]
- Biomaterials. 2022 Oct:289:121800. [Abstract]
- J Exp Clin Cancer Res. 2023 May 4;42(1):111. [Abstract]
- J Exp Clin Cancer Res. 2022 Oct 5;41(1):293. [Abstract]
- J Exp Clin Cancer Res. 2021 Nov 25;40(1):373. [Abstract]
- J Nanobiotechnology. 2022 Jul 6;20(1):315. [Abstract]
- Sci Adv. 2026 Jun 26;12(26):eadz3351. [Abstract]
- Sci Adv. 2024 Dec 13;10(50):eadq4274. [Abstract]
- Sci Adv. 2024 Jul 5;10(27):eadl1197. [Abstract]
- Mol Ther. 2025 Sep 10:S1525-0016(25)00732-4. [Abstract]
- Redox Biol. 2024 May 17:73:103200. [Abstract]
- Redox Biol. 2021 Jan;38:101807. [Abstract]
- J Control Release. 2023 Sep:361:161-177. [Abstract]
- Research (Wash D C). 2025 Jul 30:8:0809. [Abstract]
- J Exp Med. 2026 Apr 6;223(4):e20250978. [Abstract]
- Cell Rep Med. 2026 Feb 17;7(2):102613. [Abstract]
- Cell Rep Med. 2025 Sep 19:102357. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- J Immunother Cancer. 2024 Sep 4;12(9):e009318. [Abstract]
- Cell Rep Med. 2023 Oct 17;4(10):101234. [Abstract]
- Cell Rep Med. 2023 Feb 21;4(2):100911. [Abstract]
- Pharmacol Res. 2024 May 9:204:107208. [Abstract]
- Clin Cancer Res. 2026 Jan 21. [Abstract]
- Mater Today Bio. 2025 Jul 28:34:102153. [Abstract]
- Cancer Lett. 2026 Feb 4;642:218300.
- Cancer Lett. 2026 Apr 1:642:218300. [Abstract]
- Cancer Lett. 2025 Apr 16:217726. [Abstract]
- Cancer Lett. 2025 May 28:618:217633. [Abstract]
- Cancer Lett. 2024 Nov 28:605:217284. [Abstract]
- Cancer Lett. 2024 Apr 10:587:216696. [Abstract]
- Cancer Lett. 2023 Feb 1:554:216023. [Abstract]
- Cancer Lett. 2022 Jun 28;536:215651. [Abstract]
- Int J Biol Sci. 2022 Jul 4;18(11):4301-4315. [Abstract]
- Int J Biol Sci. 2022; 18(1):43-64.
- Cell Death Dis. 2026 Feb 23;17(1):247. [Abstract]
- Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. [Abstract]
- Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
- Cell Death Dis. 2025 Jul 15;16(1):526. [Abstract]
- Cell Death Dis. 2025 Jul 4;16(1):492. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Acta Biomater. 2023 Jul 1:164:407-421. [Abstract]
- Genes Dis. 2026 Mar 19.
- Proc Natl Acad Sci U S A. 2026 May 5;123(18):e2601788123. [Abstract]
- Cell Commun Signal. 2025 Nov 27;23(1):513. [Abstract]
- Chin Chem Lett. 2017 March.
- Int J Biol Macromol. 2025 Dec;334(Pt 1):148793. [Abstract]
- View. 2023 Nov 15.
- Acta Pharmacol Sin. 2024 Apr;45(4):844-856. [Abstract]
- Phytomedicine. 2025 Oct 8:148:157389. [Abstract]
- Phytomedicine. 2024 Sep 7:135:156022. [Abstract]
- Phytomedicine. 2024 Jul:129:155656. [Abstract]
- Phytomedicine. 2024 Jun:128:155527. [Abstract]
- Phytomedicine. 2022 Sep:104:154323. [Abstract]
- Mater Today Nano. 2024 Aug.
- Br J Pharmacol. 2021 Jun;178(12):2496-2515. [Abstract]
- J Transl Med. 2024 Dec 3;22(1):1095. [Abstract]
- J Transl Med. 2024 Dec 25;22(1):1147. [Abstract]
- J Transl Med. 2024 Jan 13;22(1):55. [Abstract]
- J Transl Med. 2023 Nov 21;21(1):838. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115389. [Abstract]
- Biomed Pharmacother. 2022 Apr:148:112713. [Abstract]
- Biomed Pharmacother. 2019 Sep:117:109185. [Abstract]
- Oncogene. 2026 Jun 10. [Abstract]
- MAbs. 2024 Jan-Dec;16(1):2438173. [Abstract]
- Oncogene. 2023 Oct;42(42):3113-3126. [Abstract]
- Cell Death Discov. 2021 May 1;7(1):89. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116476. [Abstract]
- Cell Rep. 2025 Jun 27;44(7):115925. [Abstract]
- Cell Rep. 2024 Apr 23;43(4):114088. [Abstract]
- Arch Toxicol. 2023 Dec;97(12):3209-3226. [Abstract]
- Cell Rep. 2022 Aug 16;40(7):111194. [Abstract]
- Clin Transl Med. 2026 Mar;16(3):e70638. [Abstract]
- J Med Chem. 2024 Sep 12;67(17):15816-15836. [Abstract]
- Nanoscale Horiz. 2025 Jun 23;10(7):1465-1477. [Abstract]
- Int J Nanomedicine. 2025 Dec 6:20:14613-14628. [Abstract]
- Int J Nanomedicine. 2025 Jun 4:20:7169-7183. [Abstract]
- Int J Nanomedicine. 2023 Jul 20:18:3989-4005. [Abstract]
- Mol Med. 2025 Apr 4;31(1):126. [Abstract]
- Elife. 2022 May 3;11:e69255. [Abstract]
- Phytother Res. 2022 Aug;36(8):3313-3324. [Abstract]
- Cell Mol Life Sci. 2024 Oct 5;81(1):417. [Abstract]
- Cell Mol Life Sci. 2021 Dec;78(23):7505-7518. [Abstract]
- JCI Insight. 2022 Nov 22;7(22):e159419. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Transl Res. 2023 May:255:66-76. [Abstract]
- J Mater Chem B. 2023 Nov 8;11(43):10355-10361. [Abstract]
- Biochem Pharmacol. 2025 Jul 18:241:117182. [Abstract]
- Biochem Pharmacol. 2025 Jul 18:241:117183. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116234. [Abstract]
- Biochem Pharmacol. 2021 Nov:193:114813. [Abstract]
- Cell Prolif. 2021 May;54(5):e13038. [Abstract]
- Biochem Pharmacol. 2021 Jul:189:114085. [Abstract]
- Mol Cancer Ther. 2026 Jun 13. [Abstract]
- Pharmaceutics. 2025 Jul 25;17(8):967. [Abstract]
- J Gastroenterol. 2025 May;60(5):641-657. [Abstract]
- ACS Biomater Sci Eng. 2025 Feb 10;11(2):1222-1231. [Abstract]
- J Ethnopharmacol. 2026 Feb 28:357:120890. [Abstract]
- J Ethnopharmacol. 2024 Jun 28:328:118075. [Abstract]
- Chem Biol Interact. 2024 Jan 5:387:110816. [Abstract]
- Inflamm Res. 2022 Dec;71(12):1547-1557. [Abstract]
- Chem Biol Interact. 2018 Jun 25:290:44-51. [Abstract]
- Cells. 2026 Feb 23;15(4):383. [Abstract]
- Commun Biol. 2026 Jan 16;9(1):260. [Abstract]
- Commun Biol. 2024 Dec 3;7(1):1612. [Abstract]
- Int J Mol Sci. 2026 Mar 13;27(6):2646. [Abstract]
- Int J Oncol. 2026 Jan;68(1):10. [Abstract]
- Cell Oncol (Dordr). 2025 Jun;48(3):655-671. [Abstract]
- ACS Appl Bio Mater. 2026 Jun 1;9(11):4723-4739. [Abstract]
- ACS Appl Polym Mater. 2026 Mar 11;8(6):4031-4044.
- Eur J Pharmacol. 2025 Dec 5:1008:178303. [Abstract]
- Bioorg Chem. 2025 Sep 17:165:109010. [Abstract]
- Eur J Pharmacol. 2025 Sep 15:1003:177942. [Abstract]
- Bioorg Chem. 2025 May 29:163:108636. [Abstract]
- Eur J Pharm Sci. 2025 Jan 1:204:106969. [Abstract]
- Int J Cancer. 2024 Jul 15;155(2):324-338. [Abstract]
- Int Immunopharmacol. 2023 Oct:123:110709. [Abstract]
- Molecules. 2023 Nov 12;28(22):7552. [Abstract]
- Molecules. 2022 Oct 13;27(20):6849. [Abstract]
- RSC Adv. 2022 Oct 3;12(43):28104-28112. [Abstract]
- Cell Rep Methods. 2026 Jun 15;6(6):101339. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- J Biomed Inform. 2023 Jun:142:104383. [Abstract]
- Mol Pharm. 2021 Jul 5;18(7):2495-2506. [Abstract]
- BJU Int. 2025 Nov 3. [Abstract]
- Clin Epigenetics. 2025 May 6;17(1):77. [Abstract]
- Biomed J. 2020 Aug;43(4):368-374. [Abstract]
- J Cannabis Res. 2024 May 8;6(1):22. [Abstract]
- FASEB J. 2025 Jul 31;39(14):e70802. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Apr 30:167881. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2025 Mar 31;1871(5):167814. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Transl Oncol. 2025 Dec 2:63:102624. [Abstract]
- iScience. 2025 Nov 24;28(12):114207. [Abstract]
- iScience. 2025 Apr 23;28(6):112509. [Abstract]
- Oncol Res. 2024 Nov 13;32(12):1867-1879. [Abstract]
- Transl Oncol. 2024 Jan:39:101803. [Abstract]
- iScience. 2022 Sep 6;25(10):105081. [Abstract]
- Transl Oncol. 2020 Sep;13(9):100804. [Abstract]
- Adv Ther. 2024 Jul 18.
- Sci Rep. 2025 Sep 26;15(1):33008. [Abstract]
- Sci Rep. 2024 Nov 29;14(1):29661. [Abstract]
- J Biol Chem. 2023 Aug;299(8):104984. [Abstract]
- Oncol Rep. 2022 Feb;47(2):33. [Abstract]
- Aging. 2020 Aug 28;12(16):16304-16325. [Abstract]
- J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Abstract]
- ACS Infect Dis. 2025 Oct 30. [Abstract]
- Microbiol Spectr. 2025 Sep 2;13(9):e0182025. [Abstract]
- J Pharmacol Exp Ther. 2018 Oct;367(1):20-27. [Abstract]
- Bioengineering (Basel). 2025 Oct 19;12(10):1121. [Abstract]
- Cell Signal. 2025 Jun 26:111965. [Abstract]
- Heliyon. 2024 Jun 28;10(13):e33835. [Abstract]
- Heliyon. 2022 Jun 8;8(6):e09643. [Abstract]
- Med Oncol. 2025 Dec 30;43(2):107. [Abstract]
- Transl Lung Cancer Res. 2025 Jun 30;14(6):2159-2179. [Abstract]
- Transl Lung Cancer Res. 2024 Oct 31;13(10):2698-2712. [Abstract]
- Exp Cell Res. 2020 Dec 1;397(1):112335. [Abstract]
- BMC Cancer. 2025 Dec 31. [Abstract]
- Eur J Med Res. 2025 Aug 4;30(1):704. [Abstract]
- Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):317-324. [Abstract]
- PLoS Negl Trop Dis. 2019 Aug 20;13(8):e0007681. [Abstract]
- Stem Cells Int. 2023 Jan 30:2023:6510571. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- J Pharm Pharmacol. 2025 Jan 23:rgae149. [Abstract]
- Mol Carcinog. 2024 Oct;63(10):1953-1966. [Abstract]
- Mol Carcinog. 2024 Apr;63(4):772-784. [Abstract]
- Int J Med Sci. 2022 Jan 4;19(2):286-298. [Abstract]
- J Pharm Biomed Anal. 2025 Nov 15:265:117063. [Abstract]
- Cancer Med. 2019 Oct;8(13):5903-5915. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. [Abstract]
- Curr Issues Mol Biol. 2024 Dec 11;46(12):13951-13969. [Abstract]
- Int J Hyperthermia. 2024 Feb 12;41(1):2316085. [Abstract]
- Breast Cancer Res Treat. 2023 Jul;200(2):193-201. [Abstract]
- Mol Immunol. 2019 May:109:140-148. [Abstract]
- Discov Oncol. 2025 Jan 3;16(1):3. [Abstract]
- Am J Cancer Res. 2020 Nov 1;10(11):3896-3910. [Abstract]
- Am J Cancer Res. 2020 Apr 1;10(4):1182-1193. [Abstract]
- J Cancer Res Clin Oncol. 2024 Jul 13;150(7):348. [Abstract]
- Technol Cancer Res Treat. 2024 Jan-Dec:23:15330338241241935. [Abstract]
- Onco Targets Ther. 2020 Sep 28;13:9543-9558. [Abstract]
- Onco Targets Ther. 2019 Jun 12:12:4585-4593. [Abstract]
- Invest New Drugs. 2025 Jun;43(3):728-741. [Abstract]
- Surgery. 2024 May;175(5):1264-1275. [Abstract]
- Immun Inflamm Dis. 2023 Jun;11(6):e872. [Abstract]
- Invest New Drugs. 2022 Apr;40(2):274-289. [Abstract]
- SLAS Discov. 2018 Aug;23(7):687-696. [Abstract]
- Cancer Manag Res. 2026 Jan 21;18:1-13.
- DNA Cell Biol. 2022 Feb;41(2):116-127. [Abstract]
- Clin Transl Oncol. 2022 Nov;24(11):2231-2240. [Abstract]
- PeerJ. 2025 May 30:13:e19517. [Abstract]
- Urol Oncol. 2021 Mar;39(3):194.e1-194.e7. [Abstract]
- Anticancer Drugs. 2025 Jun 13. [Abstract]
- Oncol Lett. 2023 Sep 20;26(5):473. [Abstract]
- Oncol Lett. 2021 Aug;22(2):626. [Abstract]
- Biol Pharm Bull. 2022 Mar 1;45(3):309-315. [Abstract]
- J Pancreatol. 2023 Dec 12.
- Int J Clin Exp Pathol. 2017;10(3):3033-3042.
- bioRxiv. 2026 May 23:2026.05.20.726695. [Abstract]
- medRxiv. 2026 Apr 18.
- Autophagy Rep. 2026 Feb 13;5(1):2624259. [Abstract]
- Res Sq. 2026 Jan 9.
- Res Sq. 2025 Oct 29.
- SSRN. 2025 Nov 13.
- RSC Pharm. 2025 Oct 9.
- bioRxiv. 2025 Oct 9:2025.10.08.681217. [Abstract]
- bioRxiv. 2025 Sep 21.
- University of Kansas. 2025.
- Res Sq. 2025 Sep 7.
- bioRxiv. 2025 Sep 24.
- Res Sq. 2025 Jul 30.
- Cell Biomater. 2025 Jul 22.
- Res Sq. 2025 Mar 26.
- bioRxiv. 2025 April 17.
- bioRxiv. 2025 Mar 13:2025.03.11.642569. [Abstract]
- bioRxiv. 2025 February 22.
- bioRxiv. 2025 January 02.
- bioRxiv. 2025 Jan 27:2025.01.26.634889. [Abstract]
- Patent. US20240344020A1
- Research Square Preprint. 2024 Aug 19.
- University of Western Australia. 2024 Jul 28.
- Patent. US20240344020A1.
- Research Square Preprint. 2024 Nov 06.
- Res Sq. 2024 Sep 05.
- bioRxiv. 2024 Aug 6:2024.03.21.586169. [Abstract]
- bioRxiv. 2024 June 12.
- SSRN. 2024 Mar 14.
- Research Square Preprint. 2024 Jan 8.
- bioRxiv. 2023 Sep 5.
- Universidad de Granada. 2023 Mar 27.
- bioRxiv. 2023 Feb 28.
- University of Brescia. 2023 Feb 2.
- bioRxiv. 2023 Feb 7.
- Patent. US20220362387A1.
- Research Square Print. October 6th, 2022.
- Oxid Med Cell Longev. 2022 Sep 29;2022:3243647. [Abstract]
- Research Square Preprint. 2021 Nov.
- Patent. US20210260092A1.
- Research Square Preprint. 2021 Aug.
- ÁREA DE FARMACIA Y TECNOLOGÍA FARMACÉUTICA. DEPARTAMENTO DE INGENIERÍA. 2020 Oct.
- Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):649-659. [Abstract]
- Oncotarget. 2017 Oct 6;8(52):90185-90196. [Abstract]
- Chinese Pharmacological Bulletin. 2017, 33(6): 788-792.
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
WB
DNA/RNA Synthesis アイソフォーム固有の製品をすべて表示
More
生物活性
DNA synthesis[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| 4T1 | IC50 |
7.17 μM
Compound: GEM
|
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth
Antiproliferative activity against mouse 4T1 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| 8305C | IC50 |
4.53 μM
Compound: Gemcitabine
|
Cytotoxicity against human 8305C cells after 24 hrs by MTT assay
Cytotoxicity against human 8305C cells after 24 hrs by MTT assay
|
[PMID: 24436994] |
| A2780 | IC50 |
1.5 nM
Compound: dFdc
|
Growth inhibition of A2780 cells by SRB assay
Growth inhibition of A2780 cells by SRB assay
|
[PMID: 17602464] |
| A2780 | IC50 |
15 nM
Compound: dFdc
|
Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole
Growth inhibition of A2780 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| A2780 | IC50 |
0.0166 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human A2780 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| A2780 | IC50 |
0.31 μM
Compound: Gemcitabine
|
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
Cytotoxicity against human A2780 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| A2780 | IC50 |
0.035 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human A2780 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| A2780 | IC50 |
0.32 μM
Compound: Gemcitabine
|
Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human A2780 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| A549 | IC50 |
13.1 μM
Compound: gemicitabine
|
Cytotoxicity against A549 cells after 72 hrs by SRB assay
Cytotoxicity against A549 cells after 72 hrs by SRB assay
|
[PMID: 17419604] |
| A549 | IC50 |
14 nM
Compound: dFdc
|
Growth inhibition of A549 cells by SRB assay
Growth inhibition of A549 cells by SRB assay
|
[PMID: 17602464] |
| A549 | IC50 |
225 nM
Compound: dFdc
|
Growth inhibition of A549 cells by SRB assay in presence of dipyridamole
Growth inhibition of A549 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| A549 | IC50 |
1.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| A549 | IC50 |
0.09 μM
Compound: gemcitabine
|
Cytotoxicity against human A549 cells by sulforhodamine B method
Cytotoxicity against human A549 cells by sulforhodamine B method
|
[PMID: 19691349] |
| A549 | IC50 |
0.02 μM
Compound: gemcitabine
|
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
Antiproliferative activity at human A549 cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| A549 | IC50 |
<0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| A549 | IC50 |
>1 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| A549 | IC50 |
0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| A549 | IC50 |
0.0068 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
Cytotoxicity against human A549 cells after 48 hrs by SRB assay
|
[PMID: 25874330] |
| A549 | IC50 |
0.029 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human A549 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| A549 | EC50 |
>100 μM
Compound: 11
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331] |
| A549 | IC50 |
0.26 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
Antiproliferative activity against human A549 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| A549 | IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human A549 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| A549 | IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytostatic activity against human A549 cells after 3 days by MTS assay
Cytostatic activity against human A549 cells after 3 days by MTS assay
|
[PMID: 30108897] |
| A549 | IC50 |
0.05 μM
Compound: Gemcitabine
|
Antiproliferative activity against human A549 cells after 3 days by MTS assay
Antiproliferative activity against human A549 cells after 3 days by MTS assay
|
[PMID: 30281308] |
| A549 | IC50 |
5.05 μM
Compound: 1; dFdC
|
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| A549 | IC50 |
0.044 μM
Compound: Gemcitabine
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34619466] |
| A549 | IC50 |
18.8 nM
Compound: GEM
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 34967607] |
| A549 | IC50 |
0.38 μM
Compound: GEM
|
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| A549 | IC50 |
0.65 μM
Compound: GMC
|
Photocytotoxicity in human A549 cells assessed as reduction in cell viability preincubated for 1 hr followed by visible light irradiation for 30 mins and measured after 72 hrs by MTT assay
Photocytotoxicity in human A549 cells assessed as reduction in cell viability preincubated for 1 hr followed by visible light irradiation for 30 mins and measured after 72 hrs by MTT assay
|
[PMID: 37360392] |
| A549 | IC50 |
0.75 μM
Compound: GMC
|
Dark toxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Dark toxicity in human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37360392] |
| A549 | IC50 |
0.8 μM
Compound: GMC
|
Photocytotoxicity in human A549 cells assessed as reduction in cell viability preincubated for 1 hr followed by two-photon NIR light irradiation for 30 mins and measured after 72 hrs by MTT assay
Photocytotoxicity in human A549 cells assessed as reduction in cell viability preincubated for 1 hr followed by two-photon NIR light irradiation for 30 mins and measured after 72 hrs by MTT assay
|
[PMID: 37360392] |
| A549 | IC50 |
5.35 μM
Compound: GEM
|
Anticancer activity against human A549 cells overexpressing CTSL assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Anticancer activity against human A549 cells overexpressing CTSL assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37593582] |
| A549 | IC50 |
0.69 μM
Compound: Gem
|
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
|
[PMID: 38716896] |
| A549 | IC50 |
2.69 μM
Compound: 7
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| ACHN | IC50 |
0.48 μM
Compound: Gemcitabine
|
Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay
Cytotoxicity against human ACHN cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| ASPC1 | IC50 |
4 nM
Compound: GEM
|
Cytotoxicity against human Aspc-1 cells by crystal violet staining
Cytotoxicity against human Aspc-1 cells by crystal violet staining
|
[PMID: 20930123] |
| ASPC1 | IC50 |
26.8 μM
Compound: GCT
|
Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human AsPC1 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| ASPC1 | IC50 |
29.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human ASPC1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431] |
| ASPC1 | IC50 |
35.11 μM
Compound: Gemcitabine
|
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
Anticancer activity against human ASPC1 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
|
[PMID: 34838335] |
| ASPC1 | IC50 |
7.5 μM
Compound: GEM
|
Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human ASPC1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848] |
| ASPC1 | IC50 |
>50 μM
Compound: Gem
|
Cytotoxicity against human ASPC1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human ASPC1 cells incubated for 48 hrs by MTT assay
|
[PMID: 38489997] |
| ASPC1 | IC50 |
0.5 μM
Compound: Gemcitabine
|
Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth
Cytotoxicity against human ASPC1 cells harboring KRAS G12D mutant assessed as inhibition of cell growth
|
[PMID: 38848113] |
| B16-F10 | IC50 |
0.26 μM
Compound: GEM
|
Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay
Cytotoxicity against mouse B16F10 cells assessed as decrease in cell viability after 72 hrs by MTT assay
|
[PMID: 30108970] |
| BEAS-2B | IC50 |
0.037 μM
Compound: Gemcitabine
|
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human BEAS-2B cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 34619466] |
| Bel-7402 | IC50 |
0.84 μM
Compound: Gemcitabine
|
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
Cytotoxicity against human Bel7402 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| BG-1 cell line | IC50 |
0.68 μM
Compound: dFdc
|
Inhibitory activity against BG-1 (human, breast adenocarcinoma) cell line
Inhibitory activity against BG-1 (human, breast adenocarcinoma) cell line
|
[PMID: 12954073] |
| BJ | IC50 |
9.88 μM
Compound: Gemcitabine
|
Cytotoxicity against human BJ cells after 3 days by MTT assay
Cytotoxicity against human BJ cells after 3 days by MTT assay
|
[PMID: 21711054] |
| BJ | IC50 |
>50 μM
Compound: Gemcitabine
|
Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human BJ cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| BJ | IC50 |
>50 μM
Compound: Gemcitabine
|
Cytostatic activity against human BJ cells after 3 days by MTS assay
Cytostatic activity against human BJ cells after 3 days by MTS assay
|
[PMID: 30108897] |
| BJ | IC50 |
>50 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BJ cells after 3 days by MTS assay
Antiproliferative activity against human BJ cells after 3 days by MTS assay
|
[PMID: 30281308] |
| BT-549 | GI50 |
0.004 μM
Compound: gemcitabine
|
Cytotoxicity against human BT549 cells after 5 days by SRB assay
Cytotoxicity against human BT549 cells after 5 days by SRB assay
|
[PMID: 19929004] |
| BT-549 | IC50 |
0.008 μM
Compound: Gemcitabine
|
Cytotoxicity against human BT549 cells after 3 days by MTT assay
Cytotoxicity against human BT549 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| BV-173 | IC50 |
0.001 μM
Compound: Gemcitabine
|
Cytotoxicity against human BV173 cells after 3 days by MTT assay
Cytotoxicity against human BV173 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| BXPC-3 | IC50 |
0.16 μM
Compound: dFdc
|
Inhibitory activity against BxPC3 (human,pancreas,adenocarcinoma) cell line
Inhibitory activity against BxPC3 (human,pancreas,adenocarcinoma) cell line
|
[PMID: 12954073] |
| BXPC-3 | IC50 |
2.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| BXPC-3 | GI50 |
3.64 μM
Compound: Gem
|
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
|
[PMID: 22512908] |
| BXPC-3 | GI50 |
3.64 nM
Compound: Gem
|
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 48 hrs by SRB assay
|
[PMID: 23094992] |
| BXPC-3 | IC50 |
0.67 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay
Cytostatic activity against human BxPC3 cells after 72 hrs by MTS assay
|
[PMID: 24471998] |
| BXPC-3 | EC50 |
10 nM
Compound: 1
|
Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay
Cytotoxicity against human BxPC3 cells after 5 days by PrestoBlue assay
|
[PMID: 24867590] |
| BXPC-3 | IC50 |
20.2 μM
Compound: GCT
|
Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human BxPC3 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| BXPC-3 | IC50 |
6 nM
Compound: Gemcitabine
|
Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay
Growth inhibition of human BxPC3 cells after 96 hrs by SRB assay
|
[PMID: 29356532] |
| BXPC-3 | IC50 |
5.71 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against human BxPC3 cells assessed as reduction in cell growth incubated for 72 hrs by MTS assay
|
[PMID: 31191868] |
| BXPC-3 | IC50 |
0.005 μM
Compound: 19
|
Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
Antiproliferative activity against human BXPC-3 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
|
[PMID: 32858470] |
| BXPC-3 | IC50 |
130 nM
Compound: 1; dFdC
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth measured after 72 hrs by SRB assay
|
[PMID: 33479633] |
| BXPC-3 | IC50 |
25.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human BXPC-3 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431] |
| BXPC-3 | IC50 |
0.04 μM
Compound: GEM
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848] |
| BXPC-3 | IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009] |
| BXPC-3 | IC50 |
0.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BXPC-3 cells expressing wild type KRAS cultured as 2D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human BXPC-3 cells expressing wild type KRAS cultured as 2D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 36709650] |
| BXPC-3 | IC50 |
159.5 μM
Compound: Gemcitabine
|
Antiproliferative activity against human BXPC-3 cells expressing wild type KRAS cultured as 3D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human BXPC-3 cells expressing wild type KRAS cultured as 3D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 36709650] |
| BXPC-3 | IC50 |
0.008 μM
Compound: GEM
|
Anticancer activity against human BXPC-3 cells overexpressing CTSL assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Anticancer activity against human BXPC-3 cells overexpressing CTSL assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37593582] |
| BXPC-3 | IC50 |
12.18 μM
Compound: GEM
|
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 24 hrs by WST-1 assay
|
[PMID: 37634418] |
| BXPC-3 | IC50 |
5.51 μM
Compound: GEM
|
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by WST-1 assay
|
[PMID: 37634418] |
| BXPC-3 | IC50 |
6.83 μM
Compound: GEM
|
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by WST-1 assay
Antiproliferative activity against human BXPC-3 cells assessed as inhibition of cell growth incubated for 48 hrs by WST-1 assay
|
[PMID: 37634418] |
| BXPC-3 | IC50 |
>50 μM
Compound: Gem
|
Cytotoxicity against human BXPC-3 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human BXPC-3 cells incubated for 48 hrs by MTT assay
|
[PMID: 38489997] |
| BXPC-3 | IC50 |
1.81 μM
Compound: Gemcitabine
|
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human BXPC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| C2D cell line | IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse C2D cell line assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926] |
| C2D cell line | IC50 |
3.7 nM
Compound: Gemcitabine
|
Antiproliferative activity against mouse C2D cell line
Antiproliferative activity against mouse C2D cell line
|
[PMID: 31945642] |
| C2G cell line | IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse C2G cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926] |
| C2G cell line | IC50 |
3.7 nM
Compound: Gemcitabine
|
Antiproliferative activity against mouse C2G cell line
Antiproliferative activity against mouse C2G cell line
|
[PMID: 31945642] |
| C6 | IC50 |
0.504 μM
Compound: Gemcitabine
|
Cytotoxicity against rat C6 cells after 3 days by MTT assay
Cytotoxicity against rat C6 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| Caco-2 | GI50 |
0.18 μM
Compound: gemcitabine
|
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
Antitumor activity against human CaCo2 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| Caco-2 | IC50 |
>100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human Caco2 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087] |
| Caco-2 | IC50 |
9.4 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human Caco-2 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437] |
| Caco-2 | IC50 |
1.33 μM
Compound: GEM
|
Anticancer activity against human Caco-2 cells with low CTSL expression assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Anticancer activity against human Caco-2 cells with low CTSL expression assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37593582] |
| Calu-1 | IC50 |
0.52 μM
Compound: Gemcitabine
|
Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay
Cytotoxicity against human Calu1 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| CAPAN-1 | IC50 |
19 nM
Compound: Gemcitabine
|
Growth inhibition of human Capan1 cells after 96 hrs by SRB assay
Growth inhibition of human Capan1 cells after 96 hrs by SRB assay
|
[PMID: 29356532] |
| CAPAN-1 | IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human Capan-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32007666] |
| Capan-2 | IC50 |
1.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay
Cytotoxicity against human Capan2 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| Capan-2 | IC50 |
40.791 μM
Compound: Gemcitabine
|
Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human Capan2 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782] |
| CCRF-CEM | IC50 |
130 nM
Compound: dFdc
|
Growth inhibition of CEM cells by SRB assay
Growth inhibition of CEM cells by SRB assay
|
[PMID: 17602464] |
| CCRF-CEM | IC50 |
1 μM
Compound: dFdc
|
Growth inhibition of CEM cells by SRB assay in presence of dipyridamole
Growth inhibition of CEM cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| CCRF-CEM | IC50 |
100 μM
Compound: dFdc
|
Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole
Growth inhibition of dCK deficient CEM cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| CCRF-CEM | IC50 |
50 μM
Compound: dFdc
|
Growth inhibition of dCK deficient CEM cells by SRB assay
Growth inhibition of dCK deficient CEM cells by SRB assay
|
[PMID: 17602464] |
| CCRF-CEM | IC50 |
0.069 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human CEM cells after 3 days by coulter counter analysis
Cytostatic activity against human CEM cells after 3 days by coulter counter analysis
|
[PMID: 24341356] |
| CCRF-CEM | IC50 |
7.6 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis
Cytostatic activity against human dCK-deficient CEM cells after 3 days by coulter counter analysis
|
[PMID: 24341356] |
| CCRF-CEM | IC50 |
0.086 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis
Cytostatic activity against human CEM cells after 72 hrs by coulter counter analysis
|
[PMID: 24471998] |
| CCRF-CEM | IC50 |
0.02 μM
Compound: Gemcitabine
|
Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against daunorubicin resistant human CCRF-CEM cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| CCRF-CEM | IC50 |
0.02 μM
Compound: Gemcitabine
|
Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay
Cytostatic activity against human CCRF-CEM cells after 3 days by MTS assay
|
[PMID: 30108897] |
| CCRF-CEM | IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay
Antiproliferative activity against human CCRF-CEM cells after 3 days by MTS assay
|
[PMID: 30281308] |
| CEM-DNR | IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay
Cytostatic activity against human CEM/DNR cells after 3 days by MTS assay
|
[PMID: 30108897] |
| CEM-SS | IC50 |
0.03 μM
Compound: dFdc
|
Inhibitory activity against CEM-SS (human T-4 lymphoblastoid clone) cell line
Inhibitory activity against CEM-SS (human T-4 lymphoblastoid clone) cell line
|
[PMID: 12954073] |
| CFPAC-1 | IC50 |
0.35 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
[PMID: 24631359] |
| CFPAC-1 | IC50 |
0.47 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells assessed as reduction of cell survival after 72 hrs by MTT assay
|
[PMID: 24631359] |
| CFPAC-1 | IC50 |
0.022 μM
Compound: Gemcitabine
|
Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782] |
| COLO 205 | IC50 |
0.0514 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs
Antiproliferative activity against p53 deficient human COLO205 cells after 72 hrs
|
[PMID: 18469809] |
| COLO 205 | IC50 |
3 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient COLO205 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| COLO 205 | IC50 |
3.24 μM
Compound: 7
|
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| COLO 205 | IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human COLO 205 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| COLO 320DM | IC50 |
3.92 μM
Compound: 7
|
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
Cytotoxicity against human COLO320DM cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| COLO357 | IC50 |
0.36 nM
Compound: GEM
|
Cytotoxicity against human Colo-357 cells by crystal violet staining
Cytotoxicity against human Colo-357 cells by crystal violet staining
|
[PMID: 20930123] |
| CT26 | IC50 |
0.006 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse CT26 cells after 3 days by MTT assay
Cytotoxicity against mouse CT26 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| CV-1 | IC50 |
21.9 μM
Compound: Gemcitabine
|
Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay
Cytotoxicity against african green monkey CV1 cells after 72 hrs by MTT assay
|
[PMID: 23489626] |
| DAN-G | IC50 |
3.4 nM
Compound: GEM
|
Cytotoxicity against human DAN-G cells by crystal violet staining
Cytotoxicity against human DAN-G cells by crystal violet staining
|
[PMID: 20930123] |
| DMS-53 | IC50 |
0.009 μM
Compound: gemcitabine
|
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
Antiproliferative activity at human DMS53 cells after 72 hrs by MTT assay
|
[PMID: 22861499] |
| DU-145 | IC50 |
0.0356 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against prostate carcinoma (DU-145) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| DU-145 | IC50 |
3.5 nM
Compound: gemcitabine
|
Antiproliferative activity against human DU145 cells by MTT assay
Antiproliferative activity against human DU145 cells by MTT assay
|
[PMID: 17887663] |
| DU-145 | IC50 |
213 nM
Compound: dFdC
|
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human DU145 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713] |
| DU-145 | IC50 |
399 nM
Compound: Gemcitabine
|
Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human DU-145 cells measured after 72 hrs by MTT assay
|
[PMID: 33223264] |
| EL4 | IC50 |
0.007 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse EL4 cells after 3 days by MTT assay
Cytotoxicity against mouse EL4 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| FTC-133 | IC50 |
3.36 μM
Compound: Gemcitabine
|
Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay
Cytotoxicity against human FTC-133 cells after 24 hrs by MTT assay
|
[PMID: 24436994] |
| HCT-116 | IC50 |
14.3 μM
Compound: gemzar, gemcitabine
|
Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay
Cytotoxicity against multidrug-resistant human HCT116 cells by thymidine incorporation assay
|
[PMID: 18186604] |
| HCT-116 | IC50 |
0.0097 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human HCT116 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| HCT-116 | IC50 |
0.005 μM
Compound: gemcitabine
|
Cytotoxicity against human HCT116 cells by sulforhodamine B method
Cytotoxicity against human HCT116 cells by sulforhodamine B method
|
[PMID: 19691349] |
| HCT-116 | IC50 |
0.006 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human HCT116 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| HCT-116 | IC50 |
0.32 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay
Cytotoxicity against human HCT116 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| HCT-116 | IC50 |
0.03 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| HCT-116 | IC50 |
0.41 μM
Compound: Gemcitabine
|
Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against p53 deficient human HCT116 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| HCT-116 | IC50 |
30 nM
Compound: Gemcitabine
|
Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
Growth inhibition of human HCT116 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
[PMID: 29253340] |
| HCT-116 | IC50 |
0.03 μM
Compound: Gemcitabine
|
Cytostatic activity against human HCT116 cells after 3 days by MTS assay
Cytostatic activity against human HCT116 cells after 3 days by MTS assay
|
[PMID: 30108897] |
| HCT-116 | IC50 |
0.41 μM
Compound: Gemcitabine
|
Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay
Cytostatic activity against human HCT116 p53-/- cells after 3 days by MTS assay
|
[PMID: 30108897] |
| HCT-116 | IC50 |
0.03 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT116 cells after 3 days by MTS assay
Antiproliferative activity against human HCT116 cells after 3 days by MTS assay
|
[PMID: 30281308] |
| HCT-116 | IC50 |
0.41 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay
Antiproliferative activity against p53 gene knocked out human HCT116 cells after 3 days by MTS assay
|
[PMID: 30281308] |
| HCT-116 | IC50 |
0.05 μM
Compound: Gem
|
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human HCT-116 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35300092] |
| HCT-116 | IC50 |
3.05 μM
Compound: GEM
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| HCT-116 | EC50 |
4 nM
Compound: Gem
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
|
[PMID: 37982711] |
| HCT-116 | IC50 |
7.33 μM
Compound: 7
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| HCT-15 | IC50 |
11.8 μM
Compound: gemzar, gemcitabine
|
Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay
Cytotoxicity against multidrug-resistant human HCT15 cells by thymidine incorporation assay
|
[PMID: 18186604] |
| HCT-15 | IC50 |
0.0099 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human HCT15 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| HCT-15 | GI50 |
0.003 μM
Compound: gemcitabine
|
Cytotoxicity against human HCT15 cells after 5 days by SRB assay
Cytotoxicity against human HCT15 cells after 5 days by SRB assay
|
[PMID: 19929004] |
| HCT-15 | IC50 |
0.01 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human HCT15 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| HCT-8 | IC50 |
1.74 μM
Compound: Gemcitabine
|
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT8 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| HEK293 | IC50 |
0.05 μM
Compound: Gemcitabine
|
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009] |
| HEK293 | IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytotoxicity against HEK293 cells measured after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells measured after 72 hrs by MTT assay
|
[PMID: 36692906] |
| HEK-293T | IC50 |
0.01 μM
Compound: GEM
|
Cytotoxicity against immortalized HEK-293T cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against immortalized HEK-293T cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 37593582] |
| HEL | IC50 |
0.48 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HEL cells after 48 hrs by MTT assay
Antiproliferative activity against human HEL cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| HEL | CC50 |
0.0036 μM
Compound: Gemcitabine
|
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
Cytotoxicity against human HEL cells assessed as reduce in cell growth incubated for 3 days by coulter counter analysis
|
[PMID: 33479570] |
| HeLa | IC50 |
0.008 μM
Compound: dFdc
|
Inhibitory activity against HeLa (human, epitheloid carcinoma, cervix) cell line
Inhibitory activity against HeLa (human, epitheloid carcinoma, cervix) cell line
|
[PMID: 12954073] |
| HeLa | IC50 |
>10 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs
Antiproliferative activity against p53 deficient human HeLa cells after 72 hrs
|
[PMID: 18469809] |
| HeLa | IC50 |
>10 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient HeLa cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| HeLa | IC50 |
4.12 μM
Compound: Gemcitabine
|
Cytotoxicity against human HeLa cells after 3 days by MTT assay
Cytotoxicity against human HeLa cells after 3 days by MTT assay
|
[PMID: 21711054] |
| HeLa | IC50 |
0.05 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay
Cytotoxicity against human HeLa cells after 72 hrs by resazurin assay
|
[PMID: 22944119] |
| HeLa | IC50 |
0.0099 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis
Cytostatic activity against human HeLa cells after 4 days by coulter counter analysis
|
[PMID: 24341356] |
| HeLa | IC50 |
0.9 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 96 hrs by MTT assay
|
[PMID: 24631359] |
| HeLa | IC50 |
10 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction of cell survival after 72 hrs by MTT assay
|
[PMID: 24631359] |
| HeLa | IC50 |
3.3 μM
Compound: Gemcitabine
|
Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human HeLa cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296] |
| HeLa | IC50 |
2.74 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| HeLa | IC50 |
9.42 μM
Compound: 1; dFdC
|
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| HeLa | IC50 |
1.99 μM
Compound: GEM
|
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| HeLa | IC50 |
0.24 μM
Compound: 22
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 38056297] |
| HeLa | IC50 |
3.9 μM
Compound: Gem
|
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
|
[PMID: 38716896] |
| HepG2 | IC50 |
4.9 μM
Compound: 1; dFdC
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| HepG2 | IC50 |
16.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HepG2 | IC50 |
2.46 μM
Compound: Gem
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
|
[PMID: 38716896] |
| HepG2 | IC50 |
2.97 μM
Compound: 7
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| HFF-1 | IC50 |
14.38 μM
Compound: Gemcitabine
|
Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human HFF-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009] |
| HFF-1 | IC50 |
14.4 μM
Compound: Gemcitabine
|
Cytotoxicity against HFF-1 cells measured after 72 hrs by MTT assay
Cytotoxicity against HFF-1 cells measured after 72 hrs by MTT assay
|
[PMID: 36692906] |
| HL-60 | IC50 |
0.33 μM
Compound: dFdc
|
Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
Inhibitory activity against HL-60 (human, promyelocytic leukemia) cell line
|
[PMID: 12954073] |
| HPAC | IC50 |
0.073 μM
Compound: Gemcitabine
|
Cytotoxicity against human HPAC cells after 3 days by MTT assay
Cytotoxicity against human HPAC cells after 3 days by MTT assay
|
[PMID: 21711054] |
| HT-29 | IC50 |
0.003 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against colon adenocarcinoma (HT-29) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| HT-29 | IC50 |
0.043 μM
Compound: dFdc
|
Inhibitory activity against HT-29 (human,colon,adenocarcinoma) cell line
Inhibitory activity against HT-29 (human,colon,adenocarcinoma) cell line
|
[PMID: 12954073] |
| HT-29 | GI50 |
0.03 μM
Compound: gemcitabine
|
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
Antitumor activity against human HT29 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| HT-29 | IC50 |
1.53 μM
Compound: Gemcitabine
|
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
Cytotoxicity against human HT-29 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| HT-29 | IC50 |
1.95 μM
Compound: 7
|
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay
|
[PMID: 23968824] |
| HT-29 | IC50 |
0.52 μM
Compound: Gemcitabine
|
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay
|
[PMID: 26025875] |
| HT-29 | IC50 |
>100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HT-29 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087] |
| HT-29 | IC50 |
0.07 μM
Compound: Gemcitabine
|
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human HT-29 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| HT-29 | IC50 |
176.62 nM
Compound: Gemcitabine
|
Synergistic antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs in presence of 50 nM 5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile by CC
Synergistic antiproliferative activity against human HT-29 cells assessed as inhibition of cell proliferation incubated for 72 hrs in presence of 50 nM 5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile by CC
|
[PMID: 38547734] |
| Huh-7 | CC50 |
<0.1 μM
Compound: 11
|
Cytotoxicity against human HuH7 cells by MTS assay
Cytotoxicity against human HuH7 cells by MTS assay
|
[PMID: 20580554] |
| Huh-7 | IC50 |
0.74 μM
Compound: GEM
|
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth
Antiproliferative activity against human Huh-7 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| HUVEC | IC50 |
0.003 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay
Cytotoxicity against HUVEC assessed as cell after 48 hrs by MTT assay
|
[PMID: 24631359] |
| Ishikawa | IC50 |
20.34 μM
Compound: 22
|
Cytotoxicity against human Ishikawa cells
Cytotoxicity against human Ishikawa cells
|
[PMID: 38056297] |
| Jurkat | IC50 |
0.0453 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human Jurkat cells after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| Jurkat | IC50 |
0.03 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient Jurkat cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| Jurkat | EC50 |
0.023 μM
Compound: 11
|
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human Jurkat cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331] |
| K562 | IC50 |
0.7459 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human K562 cells after 72 hrs
Antiproliferative activity against p53 deficient human K562 cells after 72 hrs
|
[PMID: 18469809] |
| K562 | GI50 |
0.32 μM
Compound: gemcitabine
|
Antitumor activity against human K562 cells after 48 hrs by MTS assay
Antitumor activity against human K562 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| K562 | IC50 |
0.6 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient K562 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| K562 | IC50 |
0.006 μM
Compound: Gemcitabine
|
Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay
Cytotoxicity against human paclitaxel resistant K562 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| K562 | IC50 |
0.718 μM
Compound: Gemcitabine
|
Cytotoxicity against human K562 cells after 3 days by MTT assay
Cytotoxicity against human K562 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| K562 | IC50 |
0.05 μM
Compound: Gemcitabine, dFdC
|
Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay
Cytotoxicity against human K562 cells assessed as reduction of cell survival after 48 hrs by MTT assay
|
[PMID: 24631359] |
| K562 | IC50 |
0.11 μM
Compound: Gemcitabine
|
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
Antiproliferative activity against human K562 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| K562 | IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human K562 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| K562 | IC50 |
0.1 μM
Compound: Gemcitabine
|
Cytostatic activity against human K562 cells after 3 days by MTS assay
Cytostatic activity against human K562 cells after 3 days by MTS assay
|
[PMID: 30108897] |
| K562 | IC50 |
0.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human K562 cells after 3 days by MTS assay
Antiproliferative activity against human K562 cells after 3 days by MTS assay
|
[PMID: 30281308] |
| KB | IC50 |
8.21 μM
Compound: 1; dFdC
|
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human KB cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| KG-1 | IC50 |
0.86 μM
Compound: Gemcitabine
|
Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay
Antiproliferative activity against human KG1 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| KG-1 | IC50 |
0.0018 μM
Compound: Gem
|
Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Antiproliferative activity against human KG-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 35300092] |
| L02 | IC50 |
5.43 μM
Compound: Gemcitabine
|
Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay
Antiproliferative activity against human HL7702 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| L02 | IC50 |
>20 μM
Compound: GCT
|
Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human LO2 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| L1210 | IC50 |
0.007 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse L1210 cells after 3 days by MTT assay
Cytotoxicity against mouse L1210 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| L1210 | IC50 |
0.013 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
Cytostatic activity against mouse L1210 cells after 2 days by coulter counter analysis
|
[PMID: 24341356] |
| L1210 | IC50 |
0.013 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis
Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counter analysis
|
[PMID: 24471998] |
| L929 | IC50 |
0.23 μM
Compound: 22
|
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability
Cytotoxicity against mouse L929 cells assessed as reduction in cell viability
|
[PMID: 38056297] |
| LNCaP | IC50 |
0.512 μM
Compound: Gemcitabine
|
Cytotoxicity against human LNCAP cells after 3 days by MTT assay
Cytotoxicity against human LNCAP cells after 3 days by MTT assay
|
[PMID: 21711054] |
| MCF-10A | IC50 |
>10 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay
Cytotoxicity against human MCF10A cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| MCF7 | IC50 |
1.66 μM
Compound: dFdc
|
Inhibitory activity against MCF-7/WT-2'' (human, breast carcinoma) cell line
Inhibitory activity against MCF-7/WT-2'' (human, breast carcinoma) cell line
|
[PMID: 12954073] |
| MCF7 | IC50 |
0.0803 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human MCF7 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| MCF7 | GI50 |
0.01 μM
Compound: gemcitabine
|
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
Antitumor activity against human MCF7 cells after 48 hrs by MTS assay
|
[PMID: 18588281] |
| MCF7 | IC50 |
3.28 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| MCF7 | IC50 |
0.08 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human MCF7 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| MCF7 | IC50 |
0.149 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
Cytotoxicity against human MCF7 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| MCF7 | IC50 |
0.06 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay
Cytotoxicity against human MCF7 cells after 72 hrs by resazurin assay
|
[PMID: 22944119] |
| MCF7 | IC50 |
0.0072 μM
Compound: 2a, dFdC, Gemcitabine
|
Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis
Cytostatic activity against human MCF7 cells after 2 days by coulter counter analysis
|
[PMID: 24341356] |
| MCF7 | IC50 |
0.15 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 26025875] |
| MCF7 | IC50 |
0.57 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs under normoxic condition by MTT assay
|
[PMID: 28075592] |
| MCF7 | IC50 |
8.9 μM
Compound: Gemcitabine
|
Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay
Cytotoxicity against human MCF7 cells incubated for 72 hrs under hypoxic condition by MTT assay
|
[PMID: 28075592] |
| MCF7 | IC50 |
38 nM
Compound: dFdC
|
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713] |
| MCF7 | IC50 |
1.4 nM
Compound: 1; dFdC
|
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633] |
| MCF7 | IC50 |
6.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437] |
| MCF7 | IC50 |
1.36 μM
Compound: GMC
|
Photocytotoxicity in human MCF7 cells assessed as reduction in cell viability preincubated for 1 hr followed by visible light irradiation for 30 mins and measured after 72 hrs by MTT assay
Photocytotoxicity in human MCF7 cells assessed as reduction in cell viability preincubated for 1 hr followed by visible light irradiation for 30 mins and measured after 72 hrs by MTT assay
|
[PMID: 37360392] |
| MCF7 | IC50 |
1.46 μM
Compound: GMC
|
Dark toxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
Dark toxicity in human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay
|
[PMID: 37360392] |
| MDA-MB-231 | IC50 |
11.4 nM
Compound: gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
Antiproliferative activity against human MDA-MB-231 cells by MTT assay
|
[PMID: 17887663] |
| MDA-MB-231 | IC50 |
0.245 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| MDA-MB-231 | IC50 |
>10 μM
Compound: gemcitabine
|
Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against gemcitabine-resistant human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 25350923] |
| MDA-MB-231 | IC50 |
0.025 μM
Compound: gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 25350923] |
| MDA-MB-231 | IC50 |
0.19 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human MDA-MB-231 cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296] |
| MDA-MB-231 | IC50 |
0.65 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 26025875] |
| MDA-MB-231 | IC50 |
1.67 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| MDA-MB-231 | IC50 |
30 nM
Compound: Gemcitabine
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by Hoechst 33258 dye based fluorescence assay
|
[PMID: 29253340] |
| MDA-MB-231 | GI50 |
0.251 nM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells
Antiproliferative activity against human MDA-MB-231 cells
|
[PMID: 29301085] |
| MDA-MB-231 | IC50 |
36.4 nM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay
|
[PMID: 29795767] |
| MDA-MB-231 | IC50 |
1567 nM
Compound: dFdC
|
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713] |
| MDA-MB-231 | IC50 |
2.1 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
Antiproliferative activity against human MDA-MB-231 cells assessed as cell viability after 24 hrs
|
[PMID: 33139111] |
| MDA-MB-231 | IC50 |
1.15 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MDA-MB-231 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
|
[PMID: 33359608] |
| MDA-MB-231 | IC50 |
8 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437] |
| MDA-MB-231 | IC50 |
2.22 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359] |
| MDA-MB-231 | IC50 |
61.5 nM
Compound: Gemcitabine
|
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
Antiproliferative activity against human MDA-MB-231 cells assessed as cell growth inhibition measured after 48 hrs by MTS assay
|
[PMID: 35737669] |
| MDA-MB-231 | IC50 |
0.818 μM
Compound: GEM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated in presence of 10 uM imatinib
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated in presence of 10 uM imatinib
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
2.01 μM
Compound: GEM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
7.21 μM
Compound: GEM
|
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth pretreated with hENT1 inhibitor, dipyridamole at 10 uM followed by compound addition
|
[PMID: 35810950] |
| MDA-MB-231 | IC50 |
3.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MDA-MB-231 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MES-SA | IC50 |
0.005 μM
Compound: Gemcitabine
|
Cytotoxicity against human MES-SA cells after 3 days by MTT assay
Cytotoxicity against human MES-SA cells after 3 days by MTT assay
|
[PMID: 21711054] |
| MES-SA/Dx5 | IC50 |
0.0092 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against uterine sarcoma (MES-SA) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| MIA PaCa-2 | GI50 |
35.83 μM
Compound: Gem
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
|
[PMID: 22512908] |
| MIA PaCa-2 | IC50 |
0.06 μM
Compound: Gemcitabine, Gemzar
|
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay
Cytotoxicity against human MIAPaCa2 cells after 72 hrs by resazurin assay
|
[PMID: 22944119] |
| MIA PaCa-2 | GI50 |
35.83 nM
Compound: Gem
|
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
Growth inhibition of human MIAPaCa2 cells after 48 hrs by SRB assay
|
[PMID: 23094992] |
| MIA PaCa-2 | IC50 |
1.04 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay
Cytostatic activity against human MIAPaCa2 cells after 72 hrs by MTS assay
|
[PMID: 24471998] |
| MIA PaCa-2 | EC50 |
2 μM
Compound: 1
|
Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay
Cytotoxicity against human MIAPaCa2 cells after 5 days by PrestoBlue assay
|
[PMID: 24867590] |
| MIA PaCa-2 | IC50 |
0.6 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay
Cytotoxicity against human MIAPaCa2 cells after 24 hrs by MTT colorimetric assay
|
[PMID: 25703296] |
| MIA PaCa-2 | EC50 |
0.0015 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as cell viability measured after 72 hrs by MTT assay
|
[PMID: 28105281] |
| MIA PaCa-2 | IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
[PMID: 29328656] |
| MIA PaCa-2 | IC50 |
3.3 μM
Compound: Gemcitabine
|
Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
Cytotoxicity against gemcitabine-resistant human MIAPaCa2 cells assessed as decrease in cell proliferation after 72 hrs by MTT assay
|
[PMID: 29328656] |
| MIA PaCa-2 | IC50 |
0.12 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay
Antiproliferative activity against human MIAPaCa2 cells after 70 hrs by alamar blue assay
|
[PMID: 29471119] |
| MIA PaCa-2 | IC50 |
0.016 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782] |
| MIA PaCa-2 | IC50 |
0.23 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
Cytotoxicity against human MIA PaCa-2 cells expressing CD73 assessed as reduction in cell viability by CCK8 assay
|
[PMID: 33359608] |
| MIA PaCa-2 | IC50 |
0.36 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by CCK-8 assay
|
[PMID: 35217359] |
| MIA PaCa-2 | IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009] |
| MIA PaCa-2 | EC50 |
2 nM
Compound: Gem
|
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
Antiproliferative activity against human MIA PaCa-2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTS assay
|
[PMID: 37982711] |
| MIA PaCa-2 | IC50 |
0.04 μM
Compound: Gemcitabine
|
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human MIA PaCa-2 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| MKN-28 | IC50 |
>100 μM
Compound: 1; dFdC
|
Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MKN28 cells after 48 hrs by sulforhodamine B assay
|
[PMID: 28495087] |
| MRC5 | IC50 |
<0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| MRC5 | IC50 |
<0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| MRC5 | IC50 |
0.0063 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay
Cytotoxicity against human MRC5 cells after 48 hrs by SRB assay
|
[PMID: 25874330] |
| MRC5 | IC50 |
0.0068 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| MRC5 | IC50 |
0.0216 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human MRC5 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| MRC5 | IC50 |
>50 μM
Compound: Gemcitabine
|
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| MRC5 | IC50 |
>50 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MRC5 cells after 3 days by MTS assay
Antiproliferative activity against human MRC5 cells after 3 days by MTS assay
|
[PMID: 30281308] |
| MRC5 | IC50 |
80 μM
Compound: Gemcitabine
|
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437] |
| MRC5 | IC50 |
35.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human MRC5 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431] |
| NCI-H146 | IC50 |
2.78 μM
Compound: Gemcitabine
|
Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay
Cytotoxicity against human NCI-H146 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| NCI-H1975 | IC50 |
>10 μM
Compound: GCT
|
Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay
Antiproliferative activity against gefitinib-resistant human NCI-H1975 cells harboring FAK after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| NCI-H23 | GI50 |
0.002 μM
Compound: gemcitabine
|
Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay
Cytotoxicity against human NCI-H23 cells after 5 days by SRB assay
|
[PMID: 19929004] |
| NCI-H460 | IC50 |
0.0078 μM
Compound: gemcitabine
|
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
In vitro cytotoxic activity against nonsmall cell lung carcinoma (NCI-H460) cells assayed by inhibition of [3H]-labeled thymidine incorporation
|
[PMID: 11728191] |
| NCI-H460 | IC50 |
10 nM
Compound: dFdc
|
Growth inhibition of H460 cells by SRB assay
Growth inhibition of H460 cells by SRB assay
|
[PMID: 17602464] |
| NCI-H460 | IC50 |
103 nM
Compound: dFdc
|
Growth inhibition of H460 cells by SRB assay in presence of dipyridamole
Growth inhibition of H460 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| NCI-H460 | IC50 |
0.23 μM
Compound: Gemcitabine
|
Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay
Cytotoxicity against human NCI-H460 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| NCI-H460 | GI50 |
2.085 nM
Compound: Gemcitabine
|
Antiproliferative activity against human H460 cells harboring dominant negative p53 construct
Antiproliferative activity against human H460 cells harboring dominant negative p53 construct
|
[PMID: 29301085] |
| NHDF | IC50 |
0.0221 μM
Compound: Gemcitabine
|
Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against NHDF expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| NHDF | IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against NHDF expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| NHDF | IC50 |
19.45 μM
Compound: 1; dFdC
|
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human NHDF cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| OVCAR-3 | IC50 |
67.18 μM
Compound: Gemcitabine
|
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human OVCAR-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| OVCAR-8 | IC50 |
0.0026 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human OVCAR8 cells after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| OVCAR-8 | IC50 |
0.003 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient OVCAR8 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| P388D1 | IC50 |
0.019 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay
Cytotoxicity against mouse P388D1 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| PANC-1 | IC50 |
5.6 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| PANC-1 | IC50 |
1 nM
Compound: GEM
|
Cytotoxicity against human PANC1 cells by crystal violet staining
Cytotoxicity against human PANC1 cells by crystal violet staining
|
[PMID: 20930123] |
| PANC-1 | IC50 |
0.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay
Cytotoxicity against human PANC1 cells after 48 hrs by WST-8 assay
|
[PMID: 22342146] |
| PANC-1 | IC50 |
>50 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs by MTT assay
|
[PMID: 23489626] |
| PANC-1 | EC50 |
611 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in absence of hENT1 inhibitor dipyridamole
|
[PMID: 24471998] |
| PANC-1 | EC50 |
>2000 μM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole
Cytotoxicity against human PANC1 cells assessed as cell viability by MTT assay in presence of hENT1 inhibitor dipyridamole
|
[PMID: 24471998] |
| PANC-1 | GI50 |
5.8 μM
Compound: Gemcitabine
|
Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay
Growth inhibition of human PANC1 cells after 72 hrs by WST8 assay
|
[PMID: 28495081] |
| PANC-1 | IC50 |
30.4 μM
Compound: GCT
|
Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay
Antiproliferative activity against human PANC1 cells after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| PANC-1 | IC50 |
0.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs under normoxic condition by MTT assay
|
[PMID: 29656202] |
| PANC-1 | IC50 |
1.7 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
Cytotoxicity against human PANC1 cells after 72 hrs under hypoxic condition by MTT assay
|
[PMID: 29656202] |
| PANC-1 | IC50 |
10.988 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay
Cytotoxicity against human PANC1 cells incubated for 24 hrs by MTT assay
|
[PMID: 30904782] |
| PANC-1 | IC50 |
0.16 μM
Compound: 1d
|
Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay
Antiinvasive activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based matrigel coated transwell assay
|
[PMID: 31026162] |
| PANC-1 | IC50 |
0.16 μM
Compound: 1d
|
Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay
Antimigratory activity against human PANC1 cells measured after 18 hrs in presence of mitomycin C using crystal violet staining by inverted microscopy-based transwell assay
|
[PMID: 31026162] |
| PANC-1 | IC50 |
5.9 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
Antiproliferative activity against human PANC1 cells assessed as reduction in cell viability after 72 hrs by WST-8 assay
|
[PMID: 31967821] |
| PANC-1 | IC50 |
0.15 μM
Compound: Gemcitabine
|
Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
Antiproliferative activity against human Panc-1 cells assessed as reduction in cell growth incubated for 72 hrs by SRB assay
|
[PMID: 32007666] |
| PANC-1 | IC50 |
0.022 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay
|
[PMID: 32736230] |
| PANC-1 | IC50 |
>500 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
Cytotoxicity against human PANC1 cells assessed as reduction in cell viability measured after 48 hrs by MTS assay
|
[PMID: 32920143] |
| PANC-1 | IC50 |
4.2 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Antiproliferative activity against human PANC-1 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 33964437] |
| PANC-1 | IC50 |
30 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human PANC-1 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431] |
| PANC-1 | IC50 |
8.3 μM
Compound: GEM
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 35380848] |
| PANC-1 | IC50 |
0.2 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
|
[PMID: 35439009] |
| PANC-1 | IC50 |
1.34 μM
Compound: GEM
|
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth
Antiproliferative activity against human PANC-1 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| PANC-1 | IC50 |
>100 μM
Compound: Gem
|
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay
Cytotoxicity against human PANC-1 cells assessed as reduction in cell viability incubated for 24 hrs in nutrient-rich Dulbecco's modified Eagle's medium by WST-8 assay
|
[PMID: 35969895] |
| PANC-1 | IC50 |
>50 μM
Compound: Gem
|
Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
Cytotoxicity against human PANC-1 cells incubated for 48 hrs by MTT assay
|
[PMID: 38489997] |
| PANC-1 | IC50 |
0.68 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| PANC-1 | IC50 |
1.25 μM
Compound: Gemcitabine
|
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
Cytotoxicity against human PANC-1 cells assessed as inhibition of cell growth incubated for 72 hrs by SRB assay
|
[PMID: 39151060] |
| PaTu 8988t | IC50 |
2.8 nM
Compound: GEM
|
Cytotoxicity against human Patu-T cells by crystal violet staining
Cytotoxicity against human Patu-T cells by crystal violet staining
|
[PMID: 20930123] |
| PC-3 | IC50 |
0.0026 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human PC3 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| PC-3 | IC50 |
0.04 μM
Compound: gemcitabine
|
Cytotoxicity against human PC3 cells by sulforhodamine B method
Cytotoxicity against human PC3 cells by sulforhodamine B method
|
[PMID: 19691349] |
| PC-3 | GI50 |
0.006 μM
Compound: gemcitabine
|
Cytotoxicity against human PC3 cells after 5 days by SRB assay
Cytotoxicity against human PC3 cells after 5 days by SRB assay
|
[PMID: 19929004] |
| PC-3 | IC50 |
0.003 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient PC3 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| PC-3 | EC50 |
0.065 μM
Compound: 11
|
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human PC3 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331] |
| PC-3 | IC50 |
0.22 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay
Antiproliferative activity against human PC-3 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| PC-3 | IC50 |
416 nM
Compound: dFdC
|
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human PC3 cells measured after 72 hrs by MTT assay
|
[PMID: 30716713] |
| PC-3 | IC50 |
546 nM
Compound: Gemcitabine
|
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
Antiproliferative activity against human PC-3 cells measured after 72 hrs by MTT assay
|
[PMID: 33223264] |
| PC-3 | IC50 |
74 nM
Compound: 1; dFdC
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 33479633] |
| PC-3 | IC50 |
0.46 μM
Compound: Gemcitabine
|
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human PC-3 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| PLC-PRF-5 | IC50 |
1.53 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay
Antiproliferative activity against human PLC-PRF-5 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| PSN1 | IC50 |
0.005 μM
Compound: 19
|
Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
Antiproliferative activity against human PSN1 cells assessed as reduction in cell viability measured for 72 hrs by CCK-8 assay
|
[PMID: 32858470] |
| PSN1 | IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PSN1 cells expressing KRAS mutant cultured as 2D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human PSN1 cells expressing KRAS mutant cultured as 2D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 36709650] |
| PSN1 | IC50 |
102.6 μM
Compound: Gemcitabine
|
Antiproliferative activity against human PSN1 cells expressing KRAS mutant cultured as 3D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Antiproliferative activity against human PSN1 cells expressing KRAS mutant cultured as 3D spheroids assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 36709650] |
| Ramos | IC50 |
>10 μM
Compound: GCT
|
Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay
Antiproliferative activity against human Ramos cells after 72 hrs by CCK8 assay
|
[PMID: 28576633] |
| RT-112 | EC50 |
1.4 nM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in absence of dCK substrate deoxycytidine
|
[PMID: 24471998] |
| RT-112 | EC50 |
104.9 nM
Compound: 1, dFdC, GEM, Gemcitabine
|
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine
Cytotoxicity against human RT112 cells assessed as cell viability by MTT assay in presence of dCK substrate deoxycytidine
|
[PMID: 24471998] |
| SCC-25 | IC50 |
0.047 μM
Compound: dFdc
|
Inhibitory activity against SCC-25 (human, squamous cell carcinoma, tongue) cell line
Inhibitory activity against SCC-25 (human, squamous cell carcinoma, tongue) cell line
|
[PMID: 12954073] |
| SF-268 | IC50 |
0.0103 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs
Antiproliferative activity against p53 deficient human SF268 cells after 72 hrs
|
[PMID: 18469809] |
| SF-268 | IC50 |
0.01 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient SF268 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| SF-539 | IC50 |
0.0198 μM
Compound: Gemcitabine
|
Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human SF539 cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| SF-539 | IC50 |
0.02 μM
Compound: Gemcitabine
|
Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human SF539 cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| SGC-7901 | IC50 |
9.32 μM
Compound: GEM
|
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth
Antiproliferative activity against human SGC-7901 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| SGC-7901 | IC50 |
3.58 μM
Compound: 7
|
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human SGC7901 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| SK-LU-1 | IC50 |
0.055 μM
Compound: dFdc
|
Inhibitory activity against SK-LU-1 (human,lung,adenocarcinoma) cell line
Inhibitory activity against SK-LU-1 (human,lung,adenocarcinoma) cell line
|
[PMID: 12954073] |
| SK-MEL-2 | IC50 |
7.11 μM
Compound: Gemcitabine
|
Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay
Cytotoxicity against human SK-MEL-2 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| SK-MES-1 | IC50 |
1.22 μM
Compound: Gemcitabine
|
Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
Cytotoxicity against human SK-MES-1 cells assessed as inhibition of cell viability incubated for 72 hrs by MTS assay
|
[PMID: 38547648] |
| SK-N-AS | IC50 |
1.1 μM
Compound: Gemcitabine
|
Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay
Cytotoxicity against human SK-N-AS cells after 3 days by MTT assay
|
[PMID: 21711054] |
| SK-OV-3 | IC50 |
>10 μM
Compound: Gemcitabine
|
Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
Cytotoxicity against human SKOV3 cells after 3 days by MTT assay
|
[PMID: 21711054] |
| SK-OV-3 | IC50 |
0.44 μM
Compound: GEM
|
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth
Antiproliferative activity against human SK-OV-3 cells assessed as inhibition of cell growth
|
[PMID: 35810950] |
| SMMC-7721 | IC50 |
1.4 μM
Compound: Gemcitabine
|
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
Anticancer activity against human SMMC-7721 cells assessed as inhibition of cell proliferation measured after 72 hrs by MTT assay
|
[PMID: 33444848] |
| SMMC-7721 | IC50 |
0.46 μM
Compound: Gem
|
Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
Cytotoxicity against human SMMC-7721 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay
|
[PMID: 38716896] |
| SNU-449 | IC50 |
>10 μM
Compound: Gemcitabine
|
Cytotoxicity against human SNU-449 cells assessed as inhibition of cell growth
Cytotoxicity against human SNU-449 cells assessed as inhibition of cell growth
|
[PMID: 38848113] |
| SW1573 | IC50 |
8.3 μM
Compound: gemicitabine
|
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
Cytotoxicity against SW1573 cells after 72 hrs by SRB assay
|
[PMID: 17419604] |
| SW1573 | IC50 |
16 nM
Compound: dFdc
|
Growth inhibition of SW1573 cells by SRB assay
Growth inhibition of SW1573 cells by SRB assay
|
[PMID: 17602464] |
| SW1573 | IC50 |
275 nM
Compound: dFdc
|
Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole
Growth inhibition of SW1573 cells by SRB assay in presence of dipyridamole
|
[PMID: 17602464] |
| SW1990 | IC50 |
1.2 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay
Cytotoxicity against human SW1990 cells after 72 hrs by MTT assay
|
[PMID: 19362474] |
| SW1990 | IC50 |
1.6 μM
Compound: Gemcitabine
|
Cytotoxic activity against human SW1990 cells
Cytotoxic activity against human SW1990 cells
|
[PMID: 24195466] |
| SW1990 | IC50 |
2.2 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability
|
[PMID: 25105722] |
| SW1990 | IC50 |
2.3 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human SW1990 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 27966950] |
| SW1990 | IC50 |
25.4 μM
Compound: Gemcitabine
|
Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
Cytotoxicity against human SW1990 assessed as cell viability measured for 72 hrs by cell titer glo luminescent assay
|
[PMID: 34342431] |
| SW1990 | IC50 |
40.19 μM
Compound: Gemcitabine
|
Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
Anticancer activity against human SW1990 cells assessed as cell growth inhibition measured after 72 hrs by Cell-Titre Glo luminescent cell viability assay
|
[PMID: 34838335] |
| SW480 | IC50 |
0.0136 μM
Compound: Gemcitabine
|
Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay
Antiproliferative activity against p53 deficient human SW480 cells after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| SW480 | IC50 |
1.7 μM
Compound: Gemcitabine
|
Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay
Antiproliferative activity against human p53 deficient SW480 cells after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| SW-620 | GI50 |
24.1 nM
Compound: Gemcitabine
|
Growth inhibition of human SW620 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs
Growth inhibition of human SW620 cells expressing p53 mutant assessed as reduction in cell growth incubated for 48 hrs
|
[PMID: 18790776] |
| SW-620 | GI50 |
0.84 nM
Compound: Gemcitabine
|
Antiproliferative activity against human SW620 cells
Antiproliferative activity against human SW620 cells
|
[PMID: 29301085] |
| SW-620 | IC50 |
5.62 μM
Compound: 7
|
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
Cytotoxicity against human SW620 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay
|
10.1039/C5MD00158G |
| T-24 | IC50 |
<0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| T-24 | IC50 |
<0.0039 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. compound for 24 hrs, LA + compound for 24 hrs additional, total 48 hrs 2:1 and 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| T-24 | IC50 |
0.0069 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells after 48 hrs by SRB assay
Cytotoxicity against human T24 cells after 48 hrs by SRB assay
|
[PMID: 25874330] |
| T-24 | IC50 |
0.017 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 5:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| T-24 | IC50 |
0.018 μM
Compound: 1, gemcitabine, GEM, dFdC
|
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
Cytotoxicity against human T24 cells treated at LA + compound sequent. LA for 24 hrs), LA + GEM (24 hrs additional, total 48 hrs) 2:1 alpha-lipoic acid to compound ratio after 48 hrs by SRB assay in presence of alpha-lipoic acid
|
[PMID: 25874330] |
| T-24 | IC50 |
10.15 μM
Compound: Cpd G
|
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
Antiproliferative activity against human T-24 cells assessed as reduction in cell viability measured upto 72 hrs by MTT assay
|
[PMID: 32827851] |
| T-24 | IC50 |
10.15 μM
Compound: Gem
|
Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay
Antiproliferative activity against human T24 cells measured after 48 hrs by MTT assay
|
[PMID: 35434624] |
| TRAMP-C1A | IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
Cytotoxicity against mouse TRAMP-C1A cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay
|
[PMID: 27010926] |
| TRAMP-C1A | IC50 |
3.7 nM
Compound: Gemcitabine
|
Antiproliferative activity against mouse TRAMP-C1A cells
Antiproliferative activity against mouse TRAMP-C1A cells
|
[PMID: 31945642] |
| TRAMP-C2H | IC50 |
0.0037 μM
Compound: Gemcitabine
|
Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay
Cytotoxicity against mouse TRAMP-C2H cells assessed as inhibition of cell growth measured after 72 hs by MTT assay
|
[PMID: 27010926] |
| TRAMP-C2H | IC50 |
3.7 nM
Compound: Gemcitabine
|
Antiproliferative activity against mouse TRAMP-C2H cells
Antiproliferative activity against mouse TRAMP-C2H cells
|
[PMID: 31945642] |
| U-266 | IC50 |
0.22 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
Antiproliferative activity against human U266 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| U2OS | IC50 |
0.0907 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay
Antiproliferative activity against human U2OS cells expressing p53 gene after 72 hrs by proliferative assay
|
[PMID: 18469809] |
| U2OS | IC50 |
0.18 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay
Antiproliferative activity against human U2OS cells expressing p53 after 72 hrs by celltiter-glo assay
|
[PMID: 20873740] |
| U2OS | IC50 |
0.18 μM
Compound: Gemcitabine
|
Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay
Cytotoxicity against human U2OS cells assessed as cell growth inhibition after 72 hrs by MTS assay
|
[PMID: 28221790] |
| U2OS | IC50 |
0.18 μM
Compound: Gemcitabine
|
Cytostatic activity against human U2OS cells after 3 days by MTS assay
Cytostatic activity against human U2OS cells after 3 days by MTS assay
|
[PMID: 30108897] |
| U2OS | IC50 |
0.18 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U2OS cells after 3 days by MTS assay
Antiproliferative activity against human U2OS cells after 3 days by MTS assay
|
[PMID: 30281308] |
| U373-MAGI | CC50 |
62 μM
Compound: dFdC, Gem, Gemcitabine
|
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
Cytotoxicity against human U373-MAGI cells by CellTitre-Glo assay
|
[PMID: 24120088] |
| U373-MAGI | EC50 |
27.5 nM
Compound: dFdC, Gem, Gemcitabine
|
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
Antiviral activity against HIV1 infected in human U373-MAGI cells incubated for 2 hrs prior to viral infection followed by compound washout after 24 hrs measured 72 hrs post-infection by flow cytometry
|
[PMID: 24120088] |
| U373-MAGI | CC50 |
284 μM
Compound: Gemcitabine
|
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
Increase of 5-Aza-C-mediated cytotoxicity against human U373-MAGI cells at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs measured after 72 hrs by Celltiter-Glo luminescent cell viability assay (Rvb = 387 uM)
|
[PMID: 27117260] |
| U373-MAGI | EC50 |
53.5 μM
Compound: Gemcitabine
|
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas
Potentiation of 5-Aza-C-induced antiviral activity against VSV-G pseudotyped HIV-1 NL4-3 infected in human U373-MAGI cells assessed as 5-Aza-C EC50 at 2.5 nM preincubated for 2 hrs followed by 5-Aza-C addition for 2 hrs and subsequent viral infection meas
|
[PMID: 27117260] |
| U-373MG ATCC | IC50 |
0.13 μM
Compound: dFdc
|
Inhibitory activity against U373-MG (human, glioblastoma) cell line
Inhibitory activity against U373-MG (human, glioblastoma) cell line
|
[PMID: 12954073] |
| U-87MG ATCC | IC50 |
1.49 μM
Compound: Gemcitabine
|
Cytotoxicity against human U87MG cells after 3 days by MTT assay
Cytotoxicity against human U87MG cells after 3 days by MTT assay
|
[PMID: 21711054] |
| U-87MG ATCC | EC50 |
>100 μM
Compound: 11
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability after 72 hrs by MTS assay
|
[PMID: 27032331] |
| U-87MG ATCC | IC50 |
5.21 μM
Compound: 1; dFdC
|
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
Cytotoxicity in human U87 cells assessed as reduction in cell viability incubated for 72 hrs by SRB assay
|
[PMID: 31400940] |
| U-87MG ATCC | IC50 |
8.2 nM
Compound: gem; dFdC
|
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay
Cytotoxicity against human U87 cells assessed as reduction in cell viability incubated for 72 hrs by AlamarBlue assay
|
[PMID: 31469566] |
| U-937 | IC50 |
0.07 μM
Compound: Gemcitabine
|
Antiproliferative activity against human U937 cells after 48 hrs by MTT assay
Antiproliferative activity against human U937 cells after 48 hrs by MTT assay
|
[PMID: 27670098] |
| Vero | CC50 |
0.0043 μM
Compound: Gemcitabine
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell growth by coulter counter analysis
|
[PMID: 33479570] |
| WM 266-4 | IC50 |
17.8 μM
Compound: GEM
|
Inhibition of cell growth in human WM266-4 cells measured after 24 hrs
Inhibition of cell growth in human WM266-4 cells measured after 24 hrs
|
[PMID: 34967607] |
Gemcitabine (15 nM, 48 h) exerts synergistic cytotoxicity with Indole-3-carbinol (I3C) (HY-N0170) in BxPC-3 cells via enhancing the I3C-induced upregulation of hENT1 protein expression in pancreatic cancer cell lines such as BxPC-3, Mia Paca-2, and PANC-1[1].
Gemcitabine (48 h) inhibits BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively[1].
Gemcitabine (10 μM, 24-72 h) induces apoptosis in PK-1 and PCI-43 human pancreatic cancer cells via activating p38 MAPK signaling pathway[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:hTERT-HPNE and BxPC-3 cells cells pretreated with I3C (50 μM) for 24 h
-
Concentration:15 nM
-
Incubation Time:48 h
-
Result:Resulted in 31% cell death of BxPC-3 cells at 15 nM.
Resulted in 72% cell death of BxPC-3 cells when combined with Indole-3-carbinol.
Did not affect hTERT-HPNE cell viability.
-
Cell Line:BxPC-3, PANC-1, Mia Paca-2, AsPC-1 cells (pretreated with I3C (50 μM) for 24 h)
-
Concentration:15 nM
-
Incubation Time:48 h
-
Result:Increased hENT1 protein expression in BxPC-3 and PANC-1 cells when combined with I3C, compared to I3C alone.
Showed no further increase in hENT1 protein expression in Mia Paca-2 cells.
Did not affect hENT1 expression in AsPC-1 cells alone.
Increased hENT1 expression to 3.4-fold in AsPC-1 cells when combined with I3C.
-
Cell Line:PK-1 and PCI-43 cells
-
Concentration:10 μM
-
Incubation Time:24 h
-
Result:Had little effect on the phosphorylation status of Akt, ERK1/2, and JNK.
Dramatically increased phosphorylation of p38 MAPK.
Gemcitabine (10 mg/kg, i.v., every 3 days for 21 days) inhibits tumor growth in 4T1 xenograft mouse model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LSL-KrasG12D/+; LSL-Trp53R172H; Pdx-1-Cre mice (1 month old)[3]
-
Dosage:50 mg/kg
-
Administration:i.p., twice weekly until the endpoint
-
Result:Significantly increased median survival and decreased the incidence and multiplicity of pancreatic adenocarcinomas.
Significantly decreased tumor size and the incidence of metastasis to the liver when combined with DMAPT (HY-16172).
Increased the levels of IL-1α, IL-1β, and IL-17 in mouse plasma.
Decreased levels of NF-κB target cytokines IL-12p40, MCP-1, and TNF-α, when combined with DMAPT.
Reduced MIP-1β and Eotaxin levels when combined with DMAPT.
-
Animal Model:Female BALB/c mice (5‑6 weeks old) subcutaneously injected with 4T1 cells[4]
-
Dosage:10 mg/kg
-
Administration:i.v., every 3 days for 21 days
-
Result:Significantly inhibited tumor growth.
Showed no significant decrease in body weight.
Exhibited mild signs of organ toxicity, including liver inflammation and lung interstitial edema.
Exhibited extensive cell atrophy and nuclear apoptosis compared with the control group.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
化学情報
-
CAS 番号 95058-81-4
-
性状 Solid
-
分子量 263.20
-
分子式 C9H11F2N3O4
-
Color White to off-white
-
SMILES
NC(C=CN1[C@H]2C(F)(F)[C@H](O)[C@@H](CO)O2)=NC1=O
-
別名
LY 188011
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (276)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Nat Med
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]2024 Mar;30(3):749-761. PMID: 38287168
Gemcitabine purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]
The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine (100 nM) treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin] for 48h.
-
Nature
2019 Oct;574(7777):264-267. PMID: 31578522 -
-
Mol Cancer
Sulindac (K-80003) with nab-paclitaxel and gemcitabine overcomes drug-resistant pancreatic cancer. [Abstract]2024 Sep 30;23(1):215. PMID: 39350121 -
Mol Cancer
2024 Apr 29;23(1):86. PMID: 38685067
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
The cell viability of the indicated T24 cells was determined after 48 h of continuous exposure to multiple concentrations of gemcitabine.
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
ATR-Chk1 pathway protein levels in the indicated T24 cells treated with 20 µg/L Gemcitabine for 6 h were determined by Western blotting.
-
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Mol Cancer
hsa_circ_0007919 induces LIG1 transcription by binding to FOXA1/TET1 to enhance the DNA damage response and promote gemcitabine resistance in pancreatic ductal adenocarcinoma. [Abstract]2023 Dec 4;22(1):195. PMID: 38044421
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
CCK-8 (0.1-102.4 µM; 24 h) analysis of the sensitivity of normal and GEM-resistant PDAC cells under different concentrations of gemcitabine (GEM).
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
Comet analysis of the DNA damage of GEM-resistant PDAC cells with or without hsa_circ_0007919 inhibition and of the DNA damage of PDAC cells with or without hsa_circ_0007919 overexpression under gemcitabine (GEM) treatment condition (200×).
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
IF analysis of γ-H2AX accumulation in GEM-resistant PDAC cells with or without hsa_circ_0007919 inhibition and of γ-H2AX accumulation in PDAC cells with or without hsa_circ_0007919 overexpression under gemcitabine (GEM) treatment condition (1000×).
Gemcitabine purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2023 Dec 4;22(1):195. [Abstract]
Expression of apoptosis-related proteins in hsa_circ_0007919-inhibited gemcitabine (GEM)-resistant PDAC cells with or without LIG1 overexpression.
-
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Adv Mater
Epigenetic Remodeling Hydrogel Patches for Multidrug-Resistant Triple-Negative Breast Cancer. [Abstract]2021 May;33(18):e2100949. PMID: 33792093 -
Cell Res
Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice. [Abstract]2020 Jul;30(7):574-589. PMID: 32341413 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Gemcitabine purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
-
Cancer Commun (Lond)
Simvastatin overcomes the pPCK1-pLDHA-SPRINGlac axis-mediated ferroptosis and chemo-immunotherapy resistance in AKT-hyperactivated intrahepatic cholangiocarcinoma. [Abstract]2025 May 29. PMID: 40443016 -
Nat Metab
Uridine-sensitized screening identifies demethoxy-coenzyme Q and NUDT5 as regulators of nucleotide synthesis. [Abstract]2025 Nov 13. PMID: 41233602 -
Cancer Res
N6-methyladenosine modification of FZR1 mRNA promotes gemcitabine resistance in pancreatic cancer. [Abstract]2023 Sep 15;83(18):3059-3076. PMID: 37326469 -
Hepatology
ID3 Promotes Stem Cell Features and Predicts Chemotherapeutic Response of Intrahepatic Cholangiocarcinoma. [Abstract]2019 May;69(5):1995-2012. PMID: 30520117 -
Nat Commun
β-Hydroxybutyrate promotes cancer metastasis through β-hydroxybutyrylation-dependent stabilization of Snail. [Abstract]2025 Jul 17;16(1):6592. PMID: 40675949 -
Nat Commun
Intrinsic temperature increase drives lipid metabolism towards ferroptosis evasion and chemotherapy resistance in pancreatic cancer. [Abstract]2024 Oct 2;15(1):8540. PMID: 39358362 -
-
Acta Pharm Sin B
A high-throughput Gaussia luciferase reporter assay for screening potential gasdermin E activators against pancreatic cancer. [Abstract]2023 Oct;13(10):4253-4272. PMID: 37799380 -
Sci Transl Med
Small-molecule screen reveals synergy of cell cycle checkpoint kinase inhibitors with DNA-damaging chemotherapies in medulloblastoma. [Abstract]2021 Jan 20;13(577):eaba7401. PMID: 33472956 -
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
Adv Sci (Weinh)
Targeting GPX4 to Induce Ferroptosis Overcomes Chemoresistance Mediated by the PAX8-AS1/GPX4 Axis in Intrahepatic Cholangiocarcinoma. [Abstract]2025 May 20:e01042. PMID: 40391780 -
Adv Sci (Weinh)
A Novel 167-Amino Acid Protein Encoded by CircPCSK6 Inhibits Intrahepatic Cholangiocarcinoma Progression via IKBα Ubiquitination. [Abstract]2025 Jan 21:e2409173. PMID: 39836545 -
Adv Sci (Weinh)
Synthetic Retinoid Sulfarotene Selectively Inhibits Tumor-Repopulating Cells of Intrahepatic Cholangiocarcinoma via Disrupting Cytoskeleton by P-Selectin/PSGL1 N-Glycosylation Blockage. [Abstract]2024 Nov 28:e2407519. PMID: 39605300 -
Adv Sci (Weinh)
Novel CAR-T Cells Specifically Targeting SIA-CIgG Demonstrate Effective Antitumor Efficacy in Bladder Cancer. [Abstract]2024 Aug 23:e2400156. PMID: 39178136 -
Adv Sci (Weinh)
Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Cancer. [Abstract]2023 Nov;10(33):e2302498. PMID: 37867243 -
Adv Sci (Weinh)
Sonodynamic Therapy of NRP2 Monoclonal Antibody-Guided MOFs@COF Targeted Disruption of Mitochondrial and Endoplasmic Reticulum Homeostasis to Induce Autophagy-Dependent Ferroptosis. [Abstract]2023 Oct;10(30):e2303872. PMID: 37661565 -
Adv Sci (Weinh)
Primary Human Pancreatic Cancer Cells Cultivation in Microfluidic Hydrogel Microcapsules for Drug Evaluation. [Abstract]2023 Apr;10(12):e2206004. PMID: 36808707 -
Adv Sci (Weinh)
Engineered EGCG-Containing Biomimetic Nanoassemblies as Effective Delivery Platform for Enhanced Cancer Therapy. [Abstract]2022 May;9(15):e2105894. PMID: 35486032 -
J Clin Invest
DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. [Abstract]2024 Mar 7;134(10):e172716. PMID: 38451729
Gemcitabine purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716. [Abstract]
The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.
-
Theranostics
Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma. [Abstract]2021 Mar 24;11(12):5650-5674. PMID: 33897873 -
-
-
J Adv Res
The aryl hydrocarbon receptor inhibits antigen presentation to promote progression of pancreatic ductal adenocarcinoma. [Abstract]2025 Nov 5:S2090-1232(25)00874-4. PMID: 41203070 -
J Adv Res
Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma. [Abstract]2025 Oct 16:S2090-1232(25)00818-5. PMID: 41109566 -
Biomaterials
2022 Oct:289:121800. PMID: 36166893 -
J Exp Clin Cancer Res
Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis. [Abstract]2023 May 4;42(1):111. PMID: 37143164 -
J Exp Clin Cancer Res
2022 Oct 5;41(1):293. PMID: 36199122 -
J Exp Clin Cancer Res
Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy. [Abstract]2021 Nov 25;40(1):373. PMID: 34823564 -
J Nanobiotechnology
IGF1 receptor-targeted black TiO2 nanoprobes for MRI-guided synergetic photothermal-chemotherapy in drug resistant pancreatic tumor. [Abstract]2022 Jul 6;20(1):315. PMID: 35794573 -
Sci Adv
Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities. [Abstract]2026 Jun 26;12(26):eadz3351. PMID: 42361179 -
Sci Adv
2024 Dec 13;10(50):eadq4274. PMID: 39661665 -
Sci Adv
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. [Abstract]2024 Jul 5;10(27):eadl1197. PMID: 38959305 -
Mol Ther
Elesclomol-copper combination synergistically targets mitochondrial metabolism in cancer stem cells to overcome chemoresistance in PDAC. [Abstract]2025 Sep 10:S1525-0016(25)00732-4. PMID: 40931516 -
Redox Biol
ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. [Abstract]2024 May 17:73:103200. PMID: 38781729 -
Redox Biol
FBW7-NRA41-SCD1 axis synchronously regulates apoptosis and ferroptosis in pancreatic cancer cells. [Abstract]2021 Jan;38:101807. PMID: 33271455 -
J Control Release
Enhancing chemotherapy for pancreatic cancer through efficient and sustained tumor microenvironment remodeling with a fibroblast-targeted nanosystem. [Abstract]2023 Sep:361:161-177. PMID: 37536546 -
Research (Wash D C)
Combinational Analysis of Metabolomic and O-GlcNAcylation Omics Reveals the HBP Metabolic Regulation of Chemoresistance via GFPT1/NR3C1 O-GlcNAcylation/GPX4 Axis. [Abstract]2025 Jul 30:8:0809. PMID: 40740652 -
J Exp Med
Macrophage anti-bacterial activity is controlled by adenylate kinase 4-mediated mitochondrial DNA synthesis. [Abstract]2026 Apr 6;223(4):e20250978. PMID: 41817449 -
Cell Rep Med
Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. [Abstract]2026 Feb 17;7(2):102613. PMID: 41707651 -
Cell Rep Med
Drug screening in 3D microtumors reveals DDR1/2-MAPK12-GLI1 as a vulnerability in cancer-associated fibroblasts. [Abstract]2025 Sep 19:102357. PMID: 40975064 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
J Immunother Cancer
Loss of Annexin A1 in macrophages restrains efferocytosis and remodels immune microenvironment in pancreatic cancer by activating the cGAS/STING pathway. [Abstract]2024 Sep 4;12(9):e009318. PMID: 39237260 -
Cell Rep Med
Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. [Abstract]2023 Oct 17;4(10):101234. PMID: 37852179 -
Cell Rep Med
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study. [Abstract]2023 Feb 21;4(2):100911. PMID: 36657446 -
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
Clin Cancer Res
Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results. [Abstract]2026 Jan 21. PMID: 41563386 -
Mater Today Bio
A polymeric nanovesicle delivers sulfopin and gemcitabine to remodel tumor microenvironment for enhanced chemoimmunotherapy against orthotopic pancreatic cancer. [Abstract]2025 Jul 28:34:102153. PMID: 40799994 -
-
Cancer Lett
2026 Apr 1:642:218300. PMID: 41651400 -
Cancer Lett
2025 Apr 16:217726. PMID: 40250791 -
Cancer Lett
Pentose phosphate recycling driven by Gli1 contributes to chemotherapy resistance in cancer cells. [Abstract]2025 May 28:618:217633. PMID: 40090571 -
Cancer Lett
Exploring epigenetic dynamics unveils a super-enhancer-mediated NDRG1-β-catenin axis in modulating gemcitabine resistance in pancreatic cancer. [Abstract]2024 Nov 28:605:217284. PMID: 39366545 -
Cancer Lett
2024 Apr 10:587:216696. PMID: 38331089
Gemcitabine purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2024 Apr 10:587:216696. [Abstract]
Endogenous LDHA was knocked out or ZDHHC9 was knocked down in SW1990 cells. Cells were then exposed to indicated concentrations of Gemcitabine hydrochloride for 72 h, and cell viability assays were performed. The IC50 of gemcitabine was calculated for each group.
-
Cancer Lett
CircPTK2/PABPC1/SETDB1 axis promotes EMT-mediated tumor metastasis and gemcitabine resistance in bladder cancer. [Abstract]2023 Feb 1:554:216023. PMID: 36436682 -
Cancer Lett
2022 Jun 28;536:215651. PMID: 35315340 -
Int J Biol Sci
YY1-induced DLEU1/miR-149-5p Promotes Malignant Biological Behavior of Cholangiocarcinoma through Upregulating YAP1/TEAD2/SOX2. [Abstract]2022 Jul 4;18(11):4301-4315. PMID: 35864972 -
-
Cell Death Dis
PRDM1 restricts bladder cancer progression and enhances chemosensitivity by suppressing OTUD6A-mediated deubiquitination of CDC6. [Abstract]2026 Feb 23;17(1):247. PMID: 41724787 -
Acta Biomater
2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907 -
Cell Death Dis
TGF-β1-mediated downregulation of L1CAM in pancreatic ductal adenocarcinoma drives upregulation of collagen 17A1 and MMP2, facilitating tumor invasiveness and metastasis. [Abstract]2025 Aug 6;16(1):592. PMID: 40770187
Gemcitabine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
Kaplan–Meier curve of #354 cells subcutaneously xenografted, treated or not with Gemcitabine hydrochloride (Gem, 100 mg/kg; i.p.; biweekly for three weeks) and/or TRL (50 mg/kg; i.p.; biweekly for three weeks).
Gemcitabine purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2025 Aug 6;16(1):592. [Abstract]
Gemcitabine hydrochloride (Gem, 100 mg/kg; i.p.; biweekly for three weeks). Left: Representative histological sections of xenografts derived from #354 cells. Tumor sections were stained with Hematoxylin & Eosin (H&E). S stroma; T tumor. Right: quantification of stroma content on H&E-stained sections.
-
Cell Death Dis
Targeted delivery of the PKMYT1 inhibitor RP-6306 mediates PANoptosis in pancreatic cancer via mitotic catastrophe. [Abstract]2025 Jul 15;16(1):526. PMID: 40664640 -
Cell Death Dis
DSG2 promotes pancreatic cancer stem cell maintenance via support of tumour and macrophage cellular cross-talk. [Abstract]2025 Jul 4;16(1):492. PMID: 40615400 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Acta Biomater
A Supramolecular Assembly Strategy for Hydrophilic Drug Delivery towards Synergistic Cancer Treatment. [Abstract]2023 Jul 1:164:407-421. PMID: 37088157 -
-
Proc Natl Acad Sci U S A
Fra-2 controls the response to the KRAS inhibitor MRTX-1133 in pancreatic ductal adenocarcinoma. [Abstract]2026 May 5;123(18):e2601788123. PMID: 42054368 -
Cell Commun Signal
Transcriptional deregulation by FOXM1-JUP signaling confers dual oncogenic drivers for pancreatic tumorigenesis and therapeutic resistance. [Abstract]2025 Nov 27;23(1):513. PMID: 41310714 -
-
Int J Biol Macromol
High-efficiency engineering of cell membrane nanovesicles with intrinsic homotypic targeting for precision cancer drug delivery. [Abstract]2025 Dec;334(Pt 1):148793. PMID: 41213369 -
-
Acta Pharmacol Sin
SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer. [Abstract]2024 Apr;45(4):844-856. PMID: 38057506 -
Phytomedicine
Jianpi Huayu decoction exerts antitumor effects in pancreatic cancer via SCD1-mediated lipid metabolism remodeling/ferroptosis axis. [Abstract]2025 Oct 8:148:157389. PMID: 41101075 -
Phytomedicine
Hypocrellin A against intrahepatic Cholangiocarcinoma via multi-target inhibition of the PI3K-AKT-mTOR, MAPK, and STAT3 signaling pathways. [Abstract]2024 Sep 7:135:156022. PMID: 39284270 -
Phytomedicine
Huaier enhances the tumor-killing effect and reverses gemcitabine-induced stemness by suppressing FoxM1. [Abstract]2024 Jul:129:155656. PMID: 38723529 -
Phytomedicine
Moracin D suppresses cell growth and induces apoptosis via targeting the XIAP/PARP1 axis in pancreatic cancer. [Abstract]2024 Jun:128:155527. PMID: 38489888 -
Phytomedicine
2022 Sep:104:154323. PMID: 35858516 -
-
Br J Pharmacol
The natural product trienomycin A is a STAT3 pathway inhibitor that exhibits potent in vitro and in vivo efficacy against pancreatic cancer. [Abstract]2021 Jun;178(12):2496-2515. PMID: 33687738 -
J Transl Med
Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis. [Abstract]2024 Dec 3;22(1):1095. PMID: 39623468 -
J Transl Med
2024 Dec 25;22(1):1147. PMID: 39722009 -
J Transl Med
Metabolic reprogramming based on RNA sequencing of gemcitabine-resistant cells reveals the FASN gene as a therapeutic for bladder cancer. [Abstract]2024 Jan 13;22(1):55. PMID: 38218866 -
J Transl Med
LIPH contributes to glycolytic phenotype in pancreatic ductal adenocarcinoma by activating LPA/LPAR axis and maintaining ALDOA stability. [Abstract]2023 Nov 21;21(1):838. PMID: 37990271 -
Biomed Pharmacother
Wee1 inhibition by MK1775 potentiates gemcitabine through accumulated replication stress leading to apoptosis in biliary tract cancer. [Abstract]2023 Oct:166:115389. PMID: 37659202 -
Biomed Pharmacother
Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. [Abstract]2022 Apr:148:112713. PMID: 35158144 -
Biomed Pharmacother
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. [Abstract]2019 Sep:117:109185. PMID: 31387179 -
Oncogene
DNA replication stress and translational repression converge to drive CDK1- and caspase-dependent apoptosis in Ewing sarcoma. [Abstract]2026 Jun 10. PMID: 42270776 -
MAbs
A TRAILR2/CDH3 bispecific antibody demonstrates selective apoptosis and tumor regression in CDH3-positive pancreatic cancer. [Abstract]2024 Jan-Dec;16(1):2438173. PMID: 39654063 -
Oncogene
CUL4B functions as a tumor suppressor in KRAS-driven lung tumors by inhibiting the recruitment of myeloid-derived suppressor cells. [Abstract]2023 Oct;42(42):3113-3126. PMID: 37653114 -
Cell Death Discov
A redox probe screens MTHFD1 as a determinant of gemcitabine chemoresistance in cholangiocarcinoma. [Abstract]2021 May 1;7(1):89. PMID: 33934113 -
Cell Rep
IGF2BP2 stabilized by USP7 promotes cancer-associated fibroblast activation and attenuates gemcitabine sensitivity in PDAC. [Abstract]2025 Nov 25;44(11):116476. PMID: 41201091 -
Cell Rep
Cingulin is an RNA-binding protein promoting pancreatic cancer through enhancing importin 7-mediated phospho-ERK nuclear translocation. [Abstract]2025 Jun 27;44(7):115925. PMID: 40580477 -
Cell Rep
IFNα-induced BST2+ tumor-associated macrophages facilitate immunosuppression and tumor growth in pancreatic cancer by ERK-CXCL7 signaling. [Abstract]2024 Apr 23;43(4):114088. PMID: 38602878 -
Arch Toxicol
SIRT3-dependent mitochondrial redox homeostasis mitigates CHK1 inhibition combined with gemcitabine treatment induced cardiotoxicity in hiPSC-CMs and mice. [Abstract]2023 Dec;97(12):3209-3226. PMID: 37798514 -
Cell Rep
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway. [Abstract]2022 Aug 16;40(7):111194. PMID: 35977495 -
Clin Transl Med
Multi-omic profiling defines three distinct molecular subtypes of urothelial carcinoma with implications for precision therapy. [Abstract]2026 Mar;16(3):e70638. PMID: 41804750 -
J Med Chem
Structure-Based Drug Design of 2-Amino-[1,1'-biphenyl]-3-carboxamide Derivatives as Selective PKMYT1 Inhibitors for the Treatment of CCNE1-Amplified Breast Cancer. [Abstract]2024 Sep 12;67(17):15816-15836. PMID: 39163619 -
Nanoscale Horiz
pH-Triggered delivery of pirarubicin-gemcitabine duo using polymeric nanoparticles for synergistic breast cancer therapy. [Abstract]2025 Jun 23;10(7):1465-1477. PMID: 40396269 -
Int J Nanomedicine
2025 Dec 6:20:14613-14628. PMID: 41383278 -
Int J Nanomedicine
Intravesical Tumor-Selective Mucoadhesive Hydrogel for Effective Chemotherapy In Murine Model. [Abstract]2025 Jun 4:20:7169-7183. PMID: 40491849 -
Int J Nanomedicine
Local Sustained Chemotherapy of Pancreatic Cancer Using Endoscopic Ultrasound-Guided Injection of Biodegradable Thermo-Sensitive Hydrogel. [Abstract]2023 Jul 20:18:3989-4005. PMID: 37496690 -
Mol Med
Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. [Abstract]2025 Apr 4;31(1):126. PMID: 40186145 -
Elife
2022 May 3;11:e69255. PMID: 35503721 -
Phytother Res
Higher efficacy of resveratrol against advanced breast cancer organoids: A comparison with that of clinically relevant drugs. [Abstract]2022 Aug;36(8):3313-3324. PMID: 35649509 -
Cell Mol Life Sci
KLF15 suppresses stemness of pancreatic cancer by decreasing USP21-mediated Nanog stability. [Abstract]2024 Oct 5;81(1):417. PMID: 39367978 -
Cell Mol Life Sci
OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1. [Abstract]2021 Dec;78(23):7505-7518. PMID: 34647142 -
JCI Insight
Augmenting chemotherapy with low-dose decitabine through an immune-independent mechanism. [Abstract]2022 Nov 22;7(22):e159419. PMID: 36227698
Gemcitabine purchased from MedChemExpress. Usage Cited in: JCI Insight. 2022 Nov 22;7(22):e159419. [Abstract]
Similarly, Gemcitabine hydrochloride (Gem, 150 mg/kg) + decitabine (DAC) efficacy was preserved in immune-deficient allografts in NSG mice (n = 8–9/group).
-
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Transl Res
Arsenic trioxide sensitizes pancreatic cancer cells to gemcitabine through downregulation of the TIMP1/PI3K/AKT/mTOR axis. [Abstract]2023 May:255:66-76. PMID: 36400307 -
J Mater Chem B
Engineered elastin-like polypeptide-based hydrogel delivering chemotherapeutics and PD-L1 antibodies for potentiated cancer immunotherapy. [Abstract]2023 Nov 8;11(43):10355-10361. PMID: 37817648 -
Biochem Pharmacol
Targeting BACH1/PSPH axis suppresses bladder cancer progression and gemcitabine resistance by downregulating S100A2 expression. [Abstract]2025 Jul 18:241:117182. PMID: 40684997 -
Biochem Pharmacol
Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis. [Abstract]2025 Jul 18:241:117183. PMID: 40684995 -
Biochem Pharmacol
Modulation of epithelial-mesenchymal transition by gemcitabine: Targeting ionizing radiation-induced cellular senescence in lung cancer cell. [Abstract]2024 Jun:224:116234. PMID: 38670436 -
Biochem Pharmacol
Chrysin induces autophagy-dependent ferroptosis to increase chemosensitivity to gemcitabine by targeting CBR1 in pancreatic cancer cells. [Abstract]2021 Nov:193:114813. PMID: 34673014 -
Cell Prolif
2021 May;54(5):e13038. PMID: 33793020 -
Biochem Pharmacol
TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer. [Abstract]2021 Jul:189:114085. PMID: 32522594 -
Mol Cancer Ther
Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]2026 Jun 13. PMID: 42295240 -
Pharmaceutics
A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. [Abstract]2025 Jul 25;17(8):967. PMID: 40870990 -
J Gastroenterol
Ferroptosis- and stemness inhibition-mediated therapeutic potency of ferrous oxide nanoparticles-diethyldithiocarbamate using a co-spheroid 3D model of pancreatic cancer. [Abstract]2025 May;60(5):641-657. PMID: 39888413 -
ACS Biomater Sci Eng
Triplicate Dynamic Cell Culture Platform for Enhanced Reproducibility in Anti-Cancer Drug Testing. [Abstract]2025 Feb 10;11(2):1222-1231. PMID: 39809465 -
J Ethnopharmacol
Paris polyphylla Smith var. yunnanensis-derived saponins potentiate the antitumor activity of GPX4 inhibitors. [Abstract]2026 Feb 28:357:120890. PMID: 41232632 -
J Ethnopharmacol
A metabolomics approach reveals metabolic disturbance of human cholangiocarcinoma cells after parthenolide treatment. [Abstract]2024 Jun 28:328:118075. PMID: 38513779 -
Chem Biol Interact
Targeting PKM2 improves the gemcitabine sensitivity of intrahepatic cholangiocarcinoma cells via inhibiting β-catenin signaling pathway. [Abstract]2024 Jan 5:387:110816. PMID: 38000456
Gemcitabine purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2024 Jan 5:387:110816. [Abstract]
The impact of PKM2 knockdown on gemcitabine sensitivity in ICC cells was assessed by CCK-8 assays. The cells were exposed to Gemcitabine hydrochloride (0.01-100 μM) for a duration of 72 h.
-
Inflamm Res
C/EBPβ enhances immunosuppression activity of myeloid-derived suppressor cells by a P300-mediated acetylation modification. [Abstract]2022 Dec;71(12):1547-1557. PMID: 36301341 -
Chem Biol Interact
Licoricidin enhances gemcitabine-induced cytotoxicity in osteosarcoma cells by suppressing the Akt and NF-κB signal pathways. [Abstract]2018 Jun 25:290:44-51. PMID: 29782821
Gemcitabine purchased from MedChemExpress. Usage Cited in: Chem Biol Interact. 2018 Jun 25:290:44-51. [Abstract]
U2OS and MG-63 cells are treated with Gemcitabine, Licoricidin, or Gemcitabine+Licoricidin for 24 h, followed by the determination of active caspse-3 protein level using western blot. Cells without treatment are used as Control.
-
Cells
A Comprehensive Adenoid Cystic Carcinoma-Derived Organoid Platform for Disease Modeling and Drug Screening Captures Interpatient Heterogeneity. [Abstract]2026 Feb 23;15(4):383. PMID: 41744826 -
Commun Biol
Targeting PAK4 promotes Gemcitabine-induced pyroptosis in pancreatic cancer via NLRP1/caspase-3/GSDME axis. [Abstract]2026 Jan 16;9(1):260. PMID: 41540224 -
Commun Biol
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]2024 Dec 3;7(1):1612. PMID: 39627437 -
Int J Mol Sci
LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]2026 Mar 13;27(6):2646. PMID: 41898509 -
Int J Oncol
Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. [Abstract]2026 Jan;68(1):10. PMID: 41312734 -
Cell Oncol (Dordr)
LPA released from dying cancer cells after chemotherapy inactivates Hippo signaling and promotes pancreatic cancer cell repopulation. [Abstract]2025 Jun;48(3):655-671. PMID: 39903418 -
ACS Appl Bio Mater
Amphiphilic Glycopolymer Nanoparticles for pH-Responsive Paclitaxel Delivery and Enhanced Efficacy in Pancreatic Ductal Adenocarcinoma Therapy. [Abstract]2026 Jun 1;9(11):4723-4739. PMID: 42138136 -
-
Eur J Pharmacol
Doxorubicin-mediated retardation of aggresome formation enhances Carfilzomib-induced cell death synergistically by augmenting ER stress and proapoptotic signaling. [Abstract]2025 Dec 5:1008:178303. PMID: 41183585 -
Bioorg Chem
Usenamine A, an RGS2 inhibitor, exerts anti-NSCLC activity and enhances cytotoxicity of gemcitabine by inducing ER stress and Notch1-mediated autophagy. [Abstract]2025 Sep 17:165:109010. PMID: 40974657 -
Eur J Pharmacol
VOPP1, a determinant of the sensitivity of non-small cell lung cancer cells to NAE inhibitors. [Abstract]2025 Sep 15:1003:177942. PMID: 40651787 -
Bioorg Chem
Gracillin induces mitochondria-mediated apoptosis on pancreatic ductal adenocarcinoma through disruption of redox homeostasis via inhibiting NRF2/HO-1 antioxidant axis. [Abstract]2025 May 29:163:108636. PMID: 40505322 -
Eur J Pharm Sci
In vitro and in silico study of the synergistic anticancer effect of alpinumisoflavone with gemcitabine on pancreatic ductal adenocarcinoma through suppression of ribonucleotide reductase subunit-M1. [Abstract]2025 Jan 1:204:106969. PMID: 39577749 -
Int J Cancer
Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients. [Abstract]2024 Jul 15;155(2):324-338. PMID: 38533706 -
Int Immunopharmacol
STAT3 inhibition enhances gemcitabine sensitivity in pancreatic cancer by suppressing EMT, immune escape and inducing oxidative stress damage. [Abstract]2023 Oct:123:110709. PMID: 37515849 -
Molecules
Ionophore-Based Polymeric Sensors for Potentiometric Assay of the Anticancer Drug Gemcitabine in Pharmaceutical Formulation: A Comparative Study. [Abstract]2023 Nov 12;28(22):7552. PMID: 38005274 -
Molecules
Nardoguaianone L Isolated from Nardostachys jatamansi Improved the Effect of Gemcitabine Chemotherapy via Regulating AGE Signaling Pathway in SW1990 Cells. [Abstract]2022 Oct 13;27(20):6849. PMID: 36296442 -
RSC Adv
A novel immunochemotherapy based on immunogenicity-activated and immunosuppression-reversed biomimetic nanoparticles. [Abstract]2022 Oct 3;12(43):28104-28112. PMID: 36320259 -
Cell Rep Methods
Tumor immune microenvironment reconstitution in patient-derived organoids enables therapy modeling for NSCLC. [Abstract]2026 Jun 15;6(6):101339. PMID: 42134319 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
J Biomed Inform
2023 Jun:142:104383. PMID: 37196989 -
Mol Pharm
Combining Gemcitabine-Loaded Macrophage-like Nanoparticles and Erlotinib for Pancreatic Cancer Therapy. [Abstract]2021 Jul 5;18(7):2495-2506. PMID: 34078087 -
BJU Int
Drug-releasing intravesical floating technology for sequential gemcitabine and docetaxel in non-muscle-invasive bladder cancer. [Abstract]2025 Nov 3. PMID: 41178321 -
Clin Epigenetics
Investigating the mechanisms by which low NAT1 expression in tumor cells contributes to chemo-resistance in colorectal cancer. [Abstract]2025 May 6;17(1):77. PMID: 40329330 -
Biomed J
2020 Aug;43(4):368-374. PMID: 32563698 -
J Cannabis Res
Cannabidiol's cytotoxicity in pancreatic cancer is induced via an upregulation of ceramide synthase 1 and ER stress. [Abstract]2024 May 8;6(1):22. PMID: 38720356 -
FASEB J
VGF-Derived TLQP-21 Ameliorates Tumor Progression, Pain, and Depression-Like Behaviors in an Orthotopic Mouse Model of Pancreatic Ductal Adenocarcinoma. [Abstract]2025 Jul 31;39(14):e70802. PMID: 40654186 -
Biochim Biophys Acta Mol Basis Dis
2025 Apr 30:167881. PMID: 40316058 -
Biochim Biophys Acta Mol Basis Dis
Triiodothyronine promotes the proliferation and chemoresistance of cholangiocarcinoma cells via HIF-1α/Glut1-stimulated glycolysis. [Abstract]2025 Mar 31;1871(5):167814. PMID: 40168755 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Transl Oncol
The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. [Abstract]2025 Dec 2:63:102624. PMID: 41337814 -
iScience
2025 Nov 24;28(12):114207. PMID: 41488371 -
iScience
Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death. [Abstract]2025 Apr 23;28(6):112509. PMID: 40530421 -
Oncol Res
LncRNA AFAP1-AS1 exhibits oncogenic characteristics and promotes gemcitabine-resistance of cervical cancer cells through miR-7-5p/EGFR axis. [Abstract]2024 Nov 13;32(12):1867-1879. PMID: 39574469 -
Transl Oncol
Cell surface GRP78-directed CAR-T cells are effective at treating human pancreatic cancer in preclinical models. [Abstract]2024 Jan:39:101803. PMID: 37897831 -
iScience
Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. [Abstract]2022 Sep 6;25(10):105081. PMID: 36204272 -
Transl Oncol
Low Expression of Smurf1 Enhances the Chemosensitivity of Human Colorectal Cancer to Gemcitabine and Cisplatin in Patient-Derived Xenograft Models. [Abstract]2020 Sep;13(9):100804. PMID: 32512228 -
-
Sci Rep
Identification of cytotoxic constituents from Siegesbeckiae Herba and network pharmacology prediction of their anti-pancreatic cancer mechanisms. [Abstract]2025 Sep 26;15(1):33008. PMID: 41006588 -
Sci Rep
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]2024 Nov 29;14(1):29661. PMID: 39613883 -
J Biol Chem
Vpx requires active cellular dNTP biosynthesis to effectively counteract the anti-lentivirus activity of SAMHD1 in macrophages. [Abstract]2023 Aug;299(8):104984. PMID: 37390988 -
Oncol Rep
Berberine enhances gemcitabine‑induced cytotoxicity in bladder cancer by downregulating Rad51 expression through inactivating the PI3K/Akt pathway. [Abstract]2022 Feb;47(2):33. PMID: 34935059 -
Aging
SP1-induced HOXD-AS1 promotes malignant progression of cholangiocarcinoma by regulating miR-520c-3p/MYCN. [Abstract]2020 Aug 28;12(16):16304-16325. PMID: 32857725 -
J Biol Chem
Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. [Abstract]2017 Jun 2;292(22):9136-9149. PMID: 28411237
Gemcitabine purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2017 Jun 2;292(22):9136-9149. [Abstract]
The plate clone formation of SW480 and SW620 cells with Gemcitabine (8 nM in SW480 and 16 nM in SW620) and/or PX-12 (4 μM in SW480 and 8 μM in SW620).
-
ACS Infect Dis
Targeting the Rift Valley Fever Virus Polymerase: Resistance Mechanisms and Structural Insights. [Abstract]2025 Oct 30. PMID: 41166549 -
Microbiol Spectr
Survival mechanism of pancreatic tumor bacteria and their ability to metabolize chemotherapy drugs. [Abstract]2025 Sep 2;13(9):e0182025. PMID: 40792508 -
J Pharmacol Exp Ther
Metabolic Mechanisms and a Rational Combinational Application of Carboxyamidotriazole in Fighting Pancreatic Cancer Progression after Chemotherapy. [Abstract]2018 Oct;367(1):20-27. PMID: 30002095 -
Bioengineering (Basel)
Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection. [Abstract]2025 Oct 19;12(10):1121. PMID: 41155119 -
Cell Signal
Circ_0084927 promotes progression of intrahepatic cholangiocarcinoma by sponging miR-4725-5p to activate the PDPK1/AKT/mTOR signaling pathway. [Abstract]2025 Jun 26:111965. PMID: 40581264 -
Heliyon
OIP5-AS1 enhances the malignant characteristics and resistance to chemotherapy of pancreatic cancer cells by targeting miR-30d-5p/MARCH8. [Abstract]2024 Jun 28;10(13):e33835. PMID: 39050450 -
Heliyon
Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer. [Abstract]2022 Jun 8;8(6):e09643. PMID: 35711974 -
Med Oncol
Derazantinib enhances gemcitabine efficacy in PDAC by attenuating the NF-κB and MAPK pathways to suppress MUC5AC expression. [Abstract]2025 Dec 30;43(2):107. PMID: 41467942 -
Transl Lung Cancer Res
Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. [Abstract]2025 Jun 30;14(6):2159-2179. PMID: 40673102 -
Transl Lung Cancer Res
Construction of a lung cancer 3D culture model based on alginate/gelatin micro-beads for drug evaluation. [Abstract]2024 Oct 31;13(10):2698-2712. PMID: 39507032 -
Exp Cell Res
2020 Dec 1;397(1):112335. PMID: 33132134 -
BMC Cancer
Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft. [Abstract]2025 Dec 31. PMID: 41469951 -
Eur J Med Res
Long non-coding RNA NORAD serves as a promoter of oncogenesis and inhibits ferroptosis via miR-144-3p-mTOR-ferritinophagy axis in cancer. [Abstract]2025 Aug 4;30(1):704. PMID: 40760677 -
Acta Biochim Biophys Sin (Shanghai)
Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. [Abstract]2021 Mar 2;53(3):317-324. PMID: 33432347 -
PLoS Negl Trop Dis
Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. [Abstract]2019 Aug 20;13(8):e0007681. PMID: 31430351 -
Stem Cells Int
Extracellular Vesicle-Loaded Oncogenic lncRNA NEAT1 from Adipose-Derived Mesenchymal Stem Cells Confers Gemcitabine Resistance in Pancreatic Cancer via miR-491-5p/Snail/SOCS3 Axis. [Abstract]2023 Jan 30:2023:6510571. PMID: 36762032 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
J Pharm Pharmacol
Calothrixin B by docking JAK2 is a potential therapeutic inhibitor for pancreatic ductal adenocarcinoma. [Abstract]2025 Jan 23:rgae149. PMID: 39847514 -
Mol Carcinog
YAP-LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine. [Abstract]2024 Oct;63(10):1953-1966. PMID: 39016677 -
Mol Carcinog
Liensinine inhibits progression of intrahepatic cholangiocarcinoma by regulating TGF-β1 /P-smad3 signaling through HIF-1a. [Abstract]2024 Apr;63(4):772-784. PMID: 38289159 -
Int J Med Sci
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer. [Abstract]2022 Jan 4;19(2):286-298. PMID: 35165514 -
J Pharm Biomed Anal
Integrated network pharmacology and metabolomics to investigate the effect and mechanism of nitidine chloride against cholangiocarcinoma. [Abstract]2025 Nov 15:265:117063. PMID: 40652810 -
Cancer Med
Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer. [Abstract]2019 Oct;8(13):5903-5915. PMID: 31426130 -
Naunyn Schmiedebergs Arch Pharmacol
S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway. [Abstract]2019 May;392(5):615-622. PMID: 30683944
Gemcitabine purchased from MedChemExpress. Usage Cited in: Naunyn Schmiedebergs Arch Pharmacol. 2019 May;392(5):615-622. [Abstract]
The expression level of p-JAK2, p-STAT3, Bcl-XL, and Mcl-1 in PANC-1 cells is detected by western blot analysis and is all down-regulated in the treatment groups.
-
Curr Issues Mol Biol
Transcriptomic Profiling of Carboplatin- and Paclitaxel-Resistant Lung Adenocarcinoma Cells Reveals CSF3 as a Potential Biomarker for the Carboplatin Plus Paclitaxel Doublet Regimens. [Abstract]2024 Dec 11;46(12):13951-13969. PMID: 39727962 -
Int J Hyperthermia
Validation of hyperthermia as an enhancer of chemotherapeutic efficacy: insights from a bladder cancer organoid model. [Abstract]2024 Feb 12;41(1):2316085. PMID: 38346911 -
Breast Cancer Res Treat
2023 Jul;200(2):193-201. PMID: 37204665 -
Mol Immunol
RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment. [Abstract]2019 May:109:140-148. PMID: 30951933 -
Discov Oncol
The molecular mechanism of gemcitabine in inhibiting the HIF-1α/VEGFB/FGF2/FGFR1 signaling pathway for ovarian cancer treatment. [Abstract]2025 Jan 3;16(1):3. PMID: 39752011 -
Am J Cancer Res
MOB1A regulates glucose deprivation-induced autophagy via IL6-STAT3 pathway in gallbladder carcinoma. [Abstract]2020 Nov 1;10(11):3896-3910. PMID: 33294275 -
Am J Cancer Res
Abrogation of ARF6 promotes RSL3-induced ferroptosis and mitigates gemcitabine resistance in pancreatic cancer cells. [Abstract]2020 Apr 1;10(4):1182-1193. PMID: 32368394 -
J Cancer Res Clin Oncol
Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma. [Abstract]2024 Jul 13;150(7):348. PMID: 39002018 -
Technol Cancer Res Treat
Combined OLA1 and CLEC3B Gene Is a Prognostic Signature for Hepatocellular Carcinoma and Impact Tumor Progression. [Abstract]2024 Jan-Dec:23:15330338241241935. PMID: 38564315 -
Onco Targets Ther
Targeted Inhibition of P4HB Promotes Cell Sensitivity to Gemcitabine in Urothelial Carcinoma of the Bladder. [Abstract]2020 Sep 28;13:9543-9558. PMID: 33061438 -
Onco Targets Ther
Harmine suppresses the proliferation of pancreatic cancer cells and sensitizes pancreatic cancer to gemcitabine treatment. [Abstract]2019 Jun 12:12:4585-4593. PMID: 31354292 -
Invest New Drugs
A novel CDK4 inhibitor for myeloid protection in chemotherapy-treated triple-negative breast Cancer. [Abstract]2025 Jun;43(3):728-741. PMID: 40478388 -
Surgery
CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. [Abstract]2024 May;175(5):1264-1275. PMID: 38302326 -
Immun Inflamm Dis
Th17/Treg balance is regulated by myeloid-derived suppressor cells in experimental autoimmune myocarditis. [Abstract]2023 Jun;11(6):e872. PMID: 37382257 -
Invest New Drugs
Ad-VT enhances the sensitivity of chemotherapy-resistant lung adenocarcinoma cells to gemcitabine and paclitaxel in vitro and in vivo. [Abstract]2022 Apr;40(2):274-289. PMID: 34981275 -
SLAS Discov
A Multiplexed Screening Assay to Evaluate Chemotherapy-Induced Myelosuppression Using Healthy Peripheral Blood and Bone Marrow. [Abstract]2018 Aug;23(7):687-696. PMID: 29865911 -
-
DNA Cell Biol
The Role of Ferroptosis Signature in Overall Survival and Chemotherapy of Pancreatic Adenocarcinoma. [Abstract]2022 Feb;41(2):116-127. PMID: 34898275 -
Clin Transl Oncol
Establishment of an acquired lorlatinib-resistant cell line of non-small cell lung cancer and its mediated resistance mechanism. [Abstract]2022 Nov;24(11):2231-2240. PMID: 35852680 -
PeerJ
PLA2G16 expression predicts prognosis and gemcitabine sensitivity in patients with pancreatic cancer. [Abstract]2025 May 30:13:e19517. PMID: 40458552 -
Urol Oncol
A polymeric paste-drug formulation for local treatment of upper tract urothelial carcinoma. [Abstract]2021 Mar;39(3):194.e1-194.e7. PMID: 33250343 -
Anticancer Drugs
α-Asarone attenuates tumor-associated macrophages-induced gemcitabine resistance in pancreatic carcinoma via the transforming growth factor-beta 1/growth factor independent 1 axis. [Abstract]2025 Jun 13. PMID: 40511788 -
Oncol Lett
Identification of immunogenic cell death‑related prognostic signatures in pancreatic cancer. [Abstract]2023 Sep 20;26(5):473. PMID: 37809045 -
Oncol Lett
MicroRNA-203-3p inhibits the proliferation, invasion and migration of pancreatic cancer cells by downregulating fibroblast growth factor 2. [Abstract]2021 Aug;22(2):626. PMID: 34267818 -
Biol Pharm Bull
Synergistic Effect of Baculovirus-Mediated Endostatin and Angiostatin Combined with Gemcitabine in Hepatocellular Carcinoma. [Abstract]2022 Mar 1;45(3):309-315. PMID: 34937830 -
-
-
bioRxiv
Ferrous Iron Accumulation Is a Hallmark and Therapeutic Vulnerability of Therapy-Induced Senescence. [Abstract]2026 May 23:2026.05.20.726695. PMID: 42239384 -
-
Autophagy Rep
2026 Feb 13;5(1):2624259. PMID: 41717449 -
-
-
-
-
bioRxiv
Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]2025 Oct 9:2025.10.08.681217. PMID: 41279001 -
-
-
-
-
-
-
-
-
bioRxiv
Uridine-sensitized screening identifies genes and metabolic regulators of nucleotide synthesis. [Abstract]2025 Mar 13:2025.03.11.642569. PMID: 40161720 -
-
-
bioRxiv
TRIP13 protects pancreatic cancer cells against intrinsic and therapy-induced DNA replication stress. [Abstract]2025 Jan 27:2025.01.26.634889. PMID: 39975297 -
-
-
-
-
-
-
bioRxiv
2024 Aug 6:2024.03.21.586169. PMID: 38586030 -
-
-
-
-
-
-
-
-
-
-
Oxid Med Cell Longev
High Glucose Promotes Pancreatic Ductal Adenocarcinoma Gemcitabine Resistance and Invasion through Modulating ROS/MMP-3 Signaling Pathway. [Abstract]2022 Sep 29;2022:3243647. PMID: 36211828 -
-
-
-
-
Eur Rev Med Pharmacol Sci
Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A. [Abstract]2019 Jan;23(2):649-659. PMID: 30720173 -
Oncotarget
Role of drug-dependent transporter modulation on the chemosensitivity of cholangiocarcinoma. [Abstract]2017 Oct 6;8(52):90185-90196. PMID: 29163820 -
溶剤 & 溶解度
DMSO : 200 mg/mL (759.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 12.5 mg/mL (47.49 mM; Need ultrasonic)
H2O : 6.25 mg/mL (23.75 mM; ultrasonic and warming and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (19.00 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (19.00 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 1% DMSO 99% Saline
Solubility: ≥ 0.52 mg/mL (1.98 mM); Clear solution
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (94.98 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (288 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Wang H, et al. Enhanced efficacy of Gemcitabine by indole-3-carbinol in pancreatic cell lines: the role of human equilibrativenucleoside transporter 1. Anticancer Res. 2011 Oct;31(10):3171-80. [Content Brief]
[2]. Habiro A, et al. Involvement of p38 mitogen-activated protein kinase in gemcitabine-induced apoptosis in human pancreatic cancer cells. Biochem Biophys Res Commun. 2004 Mar 26;316(1):71-7. [Content Brief]
[3]. Yip-Schneider MT, et al. Dimethylaminoparthenolide and Gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer. 2013 Apr 17;13:194. [Content Brief]
[4]. Luo J, et al. Discovery of the late autophagy inhibitor FZU‑0045‑053 and its anti‑breast cancer and immunomodulatory effects. Int J Oncol. 2026 Jan;68(1):10. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / Ethanol / DMSO | 1 mM | 3.7994 mL | 18.9970 mL | 37.9939 mL | 94.9848 mL |
| 5 mM | 0.7599 mL | 3.7994 mL | 7.5988 mL | 18.9970 mL | |
| 10 mM | 0.3799 mL | 1.8997 mL | 3.7994 mL | 9.4985 mL | |
| 15 mM | 0.2533 mL | 1.2665 mL | 2.5329 mL | 6.3323 mL | |
| 20 mM | 0.1900 mL | 0.9498 mL | 1.8997 mL | 4.7492 mL | |
| Ethanol / DMSO | 25 mM | 0.1520 mL | 0.7599 mL | 1.5198 mL | 3.7994 mL |
| 30 mM | 0.1266 mL | 0.6332 mL | 1.2665 mL | 3.1662 mL | |
| 40 mM | 0.0950 mL | 0.4749 mL | 0.9498 mL | 2.3746 mL | |
| DMSO | 50 mM | 0.0760 mL | 0.3799 mL | 0.7599 mL | 1.8997 mL |
| 60 mM | 0.0633 mL | 0.3166 mL | 0.6332 mL | 1.5831 mL | |
| 80 mM | 0.0475 mL | 0.2375 mL | 0.4749 mL | 1.1873 mL | |
| 100 mM | 0.0380 mL | 0.1900 mL | 0.3799 mL | 0.9498 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.